预约演示
更新于：2026-09-21
Dengue vaccine tetravalent(Takeda)
更新于：2026-09-21
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 印尼 (2022-08-22), |
最高研发阶段(中国)- |
特殊审评优先审评 (美国) |
登录后查看时间轴
关联
31
项与 Dengue vaccine tetravalent(Takeda) 相关的临床试验NCT06579755
A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about the side effects of TDV in adult (45 - 60 years) and elderly (60 - 79 years) persons and about TDV's ability to create an immune response in adult and elderly persons. Another aim is to learn about the side effects of TDV in adult and elderly persons in endemic countries who have one or more additional medical conditions (called comorbidities) such as diabetes mellitus, hypertension or a chronic kidney condition.
In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first).
During the study, participants will visit their study clinic 5 times.
In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first).
During the study, participants will visit their study clinic 5 times.
开始日期2026-01-20 |
NCT07047521
A Randomized, Double-Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of a New Formulation of Tetravalent Dengue Vaccine (TDV) Versus the Current Formulation of TDV in Healthy Adults (Aged 18-60 Years) in a Non-Endemic Area for Dengue
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. The TDV in current formulation has been approved by health authorities in many countries around the world. The main aim of the study is to confirm that the TDV new formulation induces the similar immune response as approved TDV.
Healthy adults who live in an area in which dengue fever does not occur will receive 2 TDV vaccinations 3-months apart with either the new or the current TDV. Blood samples will be taken before and after the vaccinations. These are necessary to check how well the vaccine works to activate the immune system. During the study, participants will visit their study clinic 5 times.
Healthy adults who live in an area in which dengue fever does not occur will receive 2 TDV vaccinations 3-months apart with either the new or the current TDV. Blood samples will be taken before and after the vaccinations. These are necessary to check how well the vaccine works to activate the immune system. During the study, participants will visit their study clinic 5 times.
开始日期2025-11-07 |
CTIS2025-520655-92-00
An open non-randomized phase IV trial examining interfering cross-reactivity in serological diagnostics of flavivirus infections in Swedish travelers following vaccination with the live dengue vaccine Qdenga
开始日期2025-09-11 |
申办/合作机构- |
100 项与 Dengue vaccine tetravalent(Takeda) 相关的临床结果
登录后查看更多信息
100 项与 Dengue vaccine tetravalent(Takeda) 相关的转化医学
登录后查看更多信息
100 项与 Dengue vaccine tetravalent(Takeda) 相关的专利（医药）
登录后查看更多信息
157
项与 Dengue vaccine tetravalent(Takeda) 相关的文献（医药）2026-10-01·ACTA TROPICA
Neutralizing dengue antibodies after 10 years of the chimeric yellow fever tetravalent dengue vaccine (CYD-TDV) and dengue antibody cross-reactivity with SARS-CoV-2 in Indonesia
Article
作者: Alam, Anggraini ; Satari, Hindra Irawan ; Karyanti, Mulya Rahma ; Hadinegoro, Sri Rezeki ; Sasmono, R Tedjo ; Widyahening, Indah Suci ; Munasir, Zakiudin
BACKGROUND:
Dengue endemic countries were affected by the spread of COVID-19. In 2011, Indonesia participated in a multi-center phase III clinical trial of chimeric yellow fever tetravalent dengue vaccine (CYD-TDV). This study evaluates neutralizing dengue antibodies of CYD-TDV after 10 years during COVID-19 pandemic.
OBJECTIVE:
To assess neutralizing antibody against all four-dengue virus (DENV) serotypes and dengue incidence in individuals who received CYD-TDV after 10 years immunization in Indonesia. Additionally, to compare SARS-CoV-2 neutralizing antibody titers and COVID-19 incidence between dengue-vaccinated and non-vaccinated groups.
METHODS:
This study was conducted across five healthcare centers in Jakarta (June-December 2022) involving 419 participants (207 dengue-vaccinated, 212 non-vaccinated). A cross-sectional study in subset of 79 dengue-vaccinated and 80 non-vaccinated participants were measured neutralizing antibodies against DENV and SARS-CoV-2, respectively. Simultaneously, all participants were given questionnaires to assess dengue and COVID-19 history.
RESULTS:
In adolescents (12-17 years), CYD-TDV recipients had significantly higher neutralizing antibody titers against DENV-1, DENV-2, and DENV-4, but not DENV-3. While, no significant differences were observed in adults (≥18 years) in both groups. Dengue incidence was similar between dengue-vaccinated (4.8%) and non-vaccinated (5.1%) groups. The SARS-CoV-2 neutralizing antibody levels were not significantly different between groups. However, incidence of hospitalized COVID-19 were higher in the dengue-vaccinated group.
CONCLUSION:
After a decade, CYD-TDV induced higher neutralizing antibody levels significantly for DENV-1, DENV-2, and DENV-4, but not for DENV-3 in adolescents but not in adults. The SARS-CoV-2 neutralizing antibody levels were comparable between groups, However, COVID-19 hospitalizations were more frequent in dengue-vaccinated group.
2026-08-01·Archivos Argentinos de Pediatria
The current dengue vaccine landscape, with a focus onTAK-003 (Qdenga®)
Article
作者: Álvarez Rotondo, Anahí ; Marín, Gustavo H
2026-08-01·VACCINE
Beyond neutralization: A comprehensive framework for evaluating humoral immunity induced by a live-attenuated tetravalent dengue vaccine
Article
作者: Dean, Hansi ; Sharma, Mayuri ; Nascimento, Eduardo J M ; Gottardo, Raphael ; Tricou, Vianney
OBJECTIVE:
Dengue incidence is increasing worldwide. TAK-003, a live-attenuated tetravalent dengue vaccine, is licensed in several countries. Its safety, efficacy, and immunogenicity have been extensively studied and provided the roadmap for recommendations and implementation. Per WHO guidelines, the primary immunogenicity endpoint in dengue vaccine clinical trials is neutralizing antibody (NAb) titers. However, there is no established immunological correlate of protection, and dengue virus (DENV) elicits a broad range of antibody responses. This study assessed statistical and experimental methods to evaluate a wide range of antibody responses to TAK-003 as a framework for evaluating vaccine immunological signatures that may correlate with protection from dengue infection and/or disease.
METHODS:
Responses were assessed by the following immunoassays: microneutralization assay, DENV total binding IgG ELISA, anti-dengue complement antibody assay, anti-dengue non-structural protein 1 (NS1) IgG ELISA, and anti-dengue IgG avidity assay. Samples from TAK-003 vaccinated/placebo participants from several trials were tested. Results were compared for assay performance and the impact of baseline serostatus, serotype, and age on vaccine-elicited responses. Correlation analyses assessed relationships among variables. Principal component analyses (PCA) evaluated data complexity.
RESULTS:
Vaccination elicited responses to all four DENV serotypes in each assay. The magnitude of vaccine-induced responses was higher in baseline seropositive participants, but vaccine effect was stronger in baseline seronegative participants. Baseline seronegative participants had comparable DENV total binding IgG concentrations, anti-dengue IgG avidity, and anti-dengue complement antibody titer responses across all serotypes. MNT50 NAb and anti-dengue NS1 IgG responses varied by serotype. Modest to low correlations across parameters suggest that the different assays measure non-redundant vaccine-induced humoral immune responses. The major source of response variability was post-vaccination time, followed by serotype.
CONCLUSION:
TAK-003 vaccination elicited multiple non-overlapping, unique humoral immune responses. Data support including parameters in addition to NAbs to better assess vaccine-induced humoral responses.
CLINICALTRIALS:
govregistration:NCT01511250, NCT02302066, NCT02747927, NCT03423173.
144
项与 Dengue vaccine tetravalent(Takeda) 相关的新闻（医药）2026-09-18
·闻风见雨
一天读懂一家药企 · DAY 02
逐段中英对照 · 中文在上，英文在下
1781年，32岁的初代武田长兵卫在大阪道修町开了一间药铺。他从批发商手中购入和汉药，再分装卖给当地药商和医生。245年后，这家小店已变成业务遍及约80个国家和地区、年收入超过4.5万亿日元的全球药企。
In 1781, 32-year-old Chobei Takeda I opened a medicine shop in Doshomachi, Osaka, then Japan's centre of the pharmaceutical trade. He bought traditional Japanese and Chinese medicines from wholesalers, divided them into smaller lots, and sold them to local merchants and physicians. Two hundred and forty-five years later, that shop has become a global biopharmaceutical company operating in roughly 80 countries and regions, with annual revenue above JPY 4.5 trillion.
武田真正改变命运的时刻，不在江户时代，而在2019年：公司以约460亿英镑收购Shire，把罕见病和血浆衍生疗法纳入版图，也把自身推入全球前列。规模解决了“日本药企如何全球化”的问题，却留下另一个更难的考题——巨额并购形成的债务、成熟产品专利到期，以及下一代产品能否及时接棒。
The event that reshaped modern Takeda did not happen in the Edo period. It came in 2019, when the company completed its approximately £46 billion acquisition of Shire. The transaction added rare diseases and plasma-derived therapies, pushed Takeda into the global top tier and created a much broader commercial platform. It also left a harder question: can the company convert scale into durable innovation before mature products erode?
核心判断：武田的优势是一个跨胃肠、血浆制品、罕见病、肿瘤和神经科学的均衡组合，以及Shire并购带来的全球商业平台；它的关键变量，是三款后期资产能否按期获批并长成新支柱；最大风险，则是Entyvio集中度、专利与仿制药侵蚀、仍偏高的杠杆和诉讼不确定性同时出现。
Investment frame: Takeda's strength is a diversified platform spanning gastrointestinal disease, plasma-derived therapies, rare diseases, oncology and neuroscience. Its critical variable is whether three late-stage assets can become meaningful successors. Its central risk is the simultaneous pressure of Entyvio concentration, loss of exclusivity, leverage, litigation and launch execution.一、它怎样诞生：从大阪药商到研究型药企
1. Origins: From a Medicine Merchant to an R&D-Based Company
武田的起点不是实验室，而是流通与信用。初代武田长兵卫在日本药材交易中心道修町立足，靠的是对药材质量和公平交易的重视。1871年，第四代长兵卫开始引进西药；1895年前后，公司进入制药生产；1914年建立自主研究活动。1943年采用今天的公司名称，1949年在日本上市。
Takeda began as a distribution business built on quality and trust, not as a laboratory. Chobei Takeda IV began importing Western medicines in 1871. Manufacturing followed around 1895, and proprietary research activities began in 1914. The company adopted its current name in 1943 and listed in Japan in 1949.
这条路径说明，武田最早的组织能力不是押中某个分子，而是不断把外部知识吸收到自己的供应、生产和研发体系。2014年，肠道选择性抗体Entyvio在美国和欧洲上市，后来成长为第一大产品。2019年收购Shire，则把公司从“以日本为根基的国际药企”推向“日本总部、全球经营”的新形态。
This history reveals a recurring organisational skill: absorbing external knowledge into Takeda's own supply, manufacturing and research systems. Entyvio, a gut-selective antibody launched in the US and Europe in 2014, later became the company's largest product. The Shire acquisition then transformed Takeda from an international company rooted in Japan into a Japan-headquartered enterprise with a genuinely global operating model.
时间
关键节点
战略意义
1781
大阪道修町创办药材生意
建立质量与流通信用
1871–1914
引进西药、进入生产并启动自主研发
从药商转向工业化制药
1949
在日本资本市场上市
获得长期扩张的资本基础
2014
Entyvio在欧美上市
建立胃肠免疫核心支柱
2019
约460亿英镑收购Shire
获得罕见病、血浆疗法与全球规模
2026
Julie Kim出任CEO
从并购整合转入新品上市周期
ENGLISH TABLE
Year
Milestone
Strategic meaning
1781
Medicine business founded in Osaka
Quality and distribution foundations
1871–1914
Western medicines, manufacturing and research
Transition to industrial pharma
2014
Entyvio launched in the US and Europe
Established a GI growth pillar
2019
Shire acquired for about £46 billion
Global scale, rare disease and plasma assets
2026
Julie Kim became CEO
Shift from integration to launch execution二、核心产品：一款胃肠药、一个血浆平台和多条专科产品线
2. Core Portfolio: One GI Flagship, a Plasma Platform and Specialist Franchises
截至2026年3月31日的2025财年，武田收入为4.506万亿日元。增长与上市产品收入2.313万亿日元，占总收入51%，按固定汇率增长4.5%。胃肠业务占销售31%，血浆衍生疗法占23%，罕见病占17%，肿瘤占13%，神经科学占9%，疫苗约占1%。这种结构比依赖单一治疗领域的公司更分散，但第一大产品Entyvio仍贡献约21%的集团收入。
For FY2025, the year ended 31 March 2026, Takeda reported revenue of JPY 4,505.7 billion. Growth and Launch Products generated JPY 2,313.3 billion, 51% of group revenue, and grew 4.5% at constant exchange rates. Gastrointestinal products accounted for 31% of sales, plasma-derived therapies 23%, rare diseases 17%, oncology 13%, neuroscience 9% and vaccines about 1%. The portfolio is broad by therapeutic area, although Entyvio alone still generated roughly 21% of group revenue.
产品/平台
定位
FY2025公司口径Entyvio
溃疡性结肠炎、克罗恩病；肠道选择性抗α4β7抗体
9580亿日元，按固定汇率增4.2%免疫球蛋白组合
GAMMAGARD、HYQVIA、CUVITRU等血浆衍生疗法
7906亿日元，按固定汇率增4.1%Takhzyro
遗传性血管性水肿预防
2239亿日元，按固定汇率降0.4%Fruzaqla
转移性结直肠癌口服VEGFR抑制剂
551亿日元，按固定汇率增14.6%Qdenga
四价减毒活登革热疫苗
408亿日元，按固定汇率增10.7%
ENGLISH TABLE
Product/platform
Role
FY2025 company figuresEntyvio
Gut-selective anti-α4β7 antibody for ulcerative colitis and Crohn's disease
JPY 958.0bn; +4.2% CERImmunoglobulins
GAMMAGARD, HYQVIA, CUVITRU and related plasma therapies
JPY 790.6bn; +4.1% CERTakhzyro
Prevention of hereditary angioedema attacks
JPY 223.9bn; −0.4% CERFruzaqla
Oral VEGFR inhibitor for metastatic colorectal cancer
JPY 55.1bn; +14.6% CERQdenga
Live-attenuated tetravalent dengue vaccine
JPY 40.8bn; +10.7% CER
最新一季也要区分汇率与经营表现。FY2026第一季度收入1.220万亿日元，按实际汇率同比增长10.2%，但按固定汇率下降0.5%；核心营业利润3589亿日元，实际汇率增11.5%，固定汇率同样下降0.5%。日元折算带来了漂亮的表面增速，经营底色仍是Vyvanse专利到期后的负增长压力。
Currency can obscure the operating picture. FY2026 first-quarter revenue was JPY 1,219.9 billion, up 10.2% at actual exchange rates but down 0.5% at CER. Core operating profit was JPY 358.9 billion, up 11.5% at actual rates and down 0.5% at CER. The translation benefit from a weaker yen produced attractive reported growth, while the underlying business was still absorbing Vyvanse generic erosion.三、竞争优势：并购留下的不只是规模
3. Competitive Advantages: What the Shire Deal Actually Built
第一，专科商业化能力可复用。Entyvio在70多个国家获批，覆盖输注与皮下注射剂型。公司引用IQVIA数据称，它是美国炎症性肠病处方领先品牌。真实优势不只来自抗体机制，还来自消化科医生网络、支付准入、长期安全性数据和多剂型管理。
Reusable specialist-commercial infrastructure. Entyvio is approved in more than 70 countries and is available in intravenous and subcutaneous formulations. Takeda, citing IQVIA, describes it as the leading prescribed inflammatory bowel disease brand in the US. Its moat combines clinical evidence, gastroenterologist relationships, market access and formulation choice.
第二，血浆制品具有高进入门槛。免疫球蛋白从献浆、检测、分离纯化到长期放行，生产周期长、监管要求高。Shire带来的血浆采集与制造网络，使武田成为这一领域的重要全球供应商。门槛形成韧性，也意味着扩产无法像普通小分子那样迅速。
A high-barrier plasma platform. Plasma therapies require donor collection, testing, fractionation, purification and lengthy release processes. Shire brought a global collection and manufacturing network that cannot be replicated quickly. The same barrier that protects Takeda also makes capacity expansion slow and operationally sensitive.
第三，资产组合跨越多种技术与疾病。公司同时拥有抗体、血浆蛋白、口服小分子、肽类药物与疫苗，并通过外部合作补充研发。2025财年与信达生物建立肿瘤合作并支付12亿美元首付款，就是以资产为中心扩充管线的例子。
Modality and disease-area breadth. The portfolio spans antibodies, plasma proteins, small molecules, peptides and vaccines. External deals supplement internal R&D; the FY2025 oncology partnership with Innovent, which included a USD 1.2 billion upfront payment, illustrates this asset-focused approach.
第四，现金流仍可支撑转型。FY2025调整后自由现金流为6845亿日元，核心营业利润1.173万亿日元。即使成熟产品承压，公司仍有资金投入上市、研发、去杠杆和股东回报。但现金流并非无限：截至期末，调整后净债务/调整后EBITDA为2.6倍。
Cash-generative incumbents. FY2025 adjusted free cash flow was JPY 684.5 billion and Core Operating Profit was JPY 1,172.5 billion. This funds launches, research, deleveraging and shareholder returns. The constraint is leverage: adjusted net debt to adjusted EBITDA was still 2.6 times at year-end.四、市场竞争力：Entyvio是王牌，组合深度是防守
4. Market Position: Entyvio Leads, Portfolio Depth Defends
在炎症性肠病市场，Entyvio以“肠道选择性”建立差异化。VARSITY头对头研究中，溃疡性结肠炎患者第52周临床缓解率为31.3%，高于阿达木单抗的22.5%；但今天的竞争已扩展到IL-12/23、IL-23、JAK和S1P等多条路线，竞争者包括Stelara、Skyrizi、Rinvoq、Omvoh等。武田必须同时守住疗效、安全、给药便利和支付准入，而不是依赖早期领先。
Entyvio differentiated itself through gut-selective biology. In the VARSITY head-to-head trial in ulcerative colitis, 31.3% of vedolizumab-treated patients achieved clinical remission at week 52, versus 22.5% with adalimumab. Today's market, however, includes IL-12/23 and IL-23 antibodies, JAK inhibitors and S1P modulators, including brands such as Stelara, Skyrizi, Rinvoq and Omvoh. Takeda must defend efficacy, safety, convenience and payer access simultaneously.
血浆衍生疗法的竞争逻辑不同。需求受免疫缺陷、神经免疫和罕见病诊疗率推动，供给却受献浆网络、产能和监管放行限制。武田的规模是一道护城河，但CSL、Grifols等公司同样深耕多年，任何采浆不足、质量事件或扩产延迟都会直接影响销量。
Plasma-derived therapies follow a different competitive logic. Demand is supported by diagnosis in immunodeficiency, neuroimmunology and rare disease, while supply depends on donor networks, manufacturing yield and regulatory release. Scale is a moat, but CSL and Grifols have comparable depth. Collection shortages, quality events or plant delays can translate directly into missed sales.
因此，武田更像一家由多个专科平台拼成的全球药企，而不是靠单一科学叙事取胜的生物科技公司。它能用Entyvio和血浆业务的现金流孵化新药，代价是组织更复杂、资本配置更难，且每个赛道都有不同的商业规则。
Takeda is therefore best understood as a federation of specialist platforms rather than a biotechnology company built around one scientific thesis. Entyvio and plasma cash flows can incubate new launches; the trade-off is organisational complexity and difficult capital allocation across businesses with very different economics.五、未来3–5年：三款候选药决定“接棒”是否成功
5. The Next Three to Five Years: A Three-Launch Relay
Oveporexton（中国商品名ORZEYFUL）。这是一款针对1型发作性睡病核心病理——食欲素缺乏——的受体激动剂。2026年已在中国首次获批，美国和日本处于审评阶段。若能改善日间嗜睡、猝倒与夜间睡眠，它可能从症状控制走向机制替代；但罕见睡眠病的诊断率、长期安全性和支付仍需验证。
Oveporexton, branded ORZEYFUL in China. This orexin-receptor agonist targets the orexin deficiency underlying narcolepsy type 1. It received its first approval in China in 2026 and is under review in the US and Japan. The opportunity is to move beyond symptomatic stimulation toward mechanism-based treatment. Diagnosis, long-term safety and payer adoption remain open questions.
Rusfertide。这款铁调素模拟肽用于真性红细胞增多症，目标是减少放血并稳定血细胞比容。已发表的REVIVE二期随机撤药阶段中，应答率为60%，安慰剂为17%；三期结果积极且美国获优先审评。商业机会清晰，但仍须等待监管结论，并观察长期铁代谢、安全性与患者依从性。
Rusfertide. The hepcidin mimetic is designed to reduce phlebotomy and control haematocrit in polycythaemia vera. In the published randomised-withdrawal portion of the Phase 2 REVIVE study, 60% of rusfertide patients responded versus 17% on placebo. Positive Phase 3 results and FDA Priority Review support the case, but regulatory approval, long-term iron metabolism and adherence still need to be confirmed.
Zasocitinib。这款高选择性口服TYK2抑制剂用于银屑病，三期头对头研究与deucravacitinib比较取得积极结果，公司计划2026年申报、2027年上半年上市。机会在于扩大口服系统治疗市场，挑战则是已上市TYK2药物、成熟生物制剂和安全标签之间的激烈竞争。
Zasocitinib. The highly selective oral TYK2 inhibitor produced positive Phase 3 results, including a head-to-head study against deucravacitinib. Takeda plans regulatory submissions in 2026 and anticipates launch in the first half of 2027. It could expand the oral systemic psoriasis segment, but will enter a crowded market of an established TYK2 agent and mature biologics.
公司给出的FY2026预测为收入4.640万亿日元、核心营业利润1.160万亿日元、调整后自由现金流6500亿至7500亿日元；但按固定汇率的管理层指引仍是核心收入低个位数下降、核心营业利润下降5%–8%。这说明2026不是利润收获年，而是用成熟产品现金流换取新产品上市的投资年。真正的验证期在2027年以后：三款产品能否同步获批、获得支付并跨过早期放量曲线。
Takeda forecasts FY2026 revenue of JPY 4,640.0 billion, Core Operating Profit of JPY 1,160.0 billion and adjusted free cash flow of JPY 650–750 billion. Yet management guidance at CER calls for a low-single-digit revenue decline and a 5%–8% decline in Core Operating Profit. This is an investment year, not a harvest year. The real test begins in FY2027, when approvals must translate into reimbursement, physician adoption and repeat demand.六、危机与挑战：四个不能被汇率掩盖的问题
6. Risks and Challenges: Four Issues Currency Cannot Hide
专利悬崖。Vyvanse美国专利及儿科独占期在2023年到期，已拖累神经科学业务，FY2025该板块按固定汇率下降27.2%。Entyvio的监管独占期已进入后段，公司披露的制剂、给药和生产工艺专利部分延续至2032年；生物类似药何时进入仍不确定，但占集团收入约五分之一的产品终将面对侵蚀。
Loss of exclusivity. US patent protection and paediatric exclusivity for Vyvanse expired in 2023, contributing to a 27.2% CER decline in neuroscience revenue in FY2025. Some formulation, dosing and manufacturing patents for Entyvio extend to 2032, but regulatory exclusivity is already in its later phase. Biosimilar timing is uncertain; eventual erosion of a product representing about one-fifth of group revenue is not.
债务与资本纪律。Shire交易让武田快速全球化，也一度显著提高杠杆。FY2025末2.6倍的调整后净债务/EBITDA低于并购完成时水平，却仍高于公司过去提出的中期2倍目标。新药上市、研发合作、股息和去杠杆都要争夺同一份现金流。
Leverage and capital discipline. The Shire deal globalised Takeda but initially lifted debt sharply. A 2.6-times adjusted net debt/adjusted EBITDA ratio is far below the post-deal level, yet remains above Takeda's earlier medium-term target of two times. Launches, partnerships, dividends and deleveraging compete for the same cash.
诉讼与合规。AMITIZA美国反垄断诉讼导致公司在FY2025计提4035亿日元法律程序拨备，将最初披露的4088亿日元营业利润修正为62亿日元，归母净利润也转为亏损1524亿日元。公司正申请判后救济并计划上诉，最终负债尚未确定。这是一个不能只看“核心利润”就忽略的尾部风险。
Litigation. The US AMITIZA antitrust verdict led Takeda to recognise JPY 403.5 billion in legal provisions for FY2025. Reported operating profit was revised from the initially announced JPY 408.8 billion to JPY 6.2 billion, and attributable net income became a JPY 152.4 billion loss. Takeda is pursuing post-trial motions and an appeal; the ultimate liability remains unresolved.
上市执行与组织转型。三款候选药集中在12–18个月内推进，任何审评延迟、标签收窄或商业启动不及预期都会放大增长缺口。与此同时，Julie Kim于2026年6月接任CEO，公司计划到FY2028实现超过2000亿日元年化节省。降本必须避免削弱医学、市场准入和研发协作。
Launch and organisational execution. Three programmes are moving through launch preparation within a concentrated 12–18-month window. Delayed reviews, narrower labels or weak uptake could enlarge the growth gap. Julie Kim became CEO in June 2026 while Takeda targets more than JPY 200 billion of annualised transformation savings by FY2028. Efficiency cannot come at the expense of medical, market-access or R&D capability.
此外，日元波动会显著改变报表增速。FY2026第一季度实际汇率增长与固定汇率下降并存，就是典型例子。判断经营质量，应优先看固定汇率收入、产品销量、净价、自由现金流和债务指标，而不是只看日元口径的同比增幅。
Foreign exchange is an additional analytical risk. The gap between actual-rate growth and CER decline in Q1 FY2026 shows why investors should prioritise CER sales, unit demand, net pricing, free cash flow and debt ratios rather than the yen-reported headline alone.七、股权与实际控制人：没有家族控股，也没有单一控制者
7. Ownership and Control: No Family Controller, No Controlling Shareholder
武田在东京证券交易所主板及纽约证券交易所上市，股权高度分散。公司2026年治理报告明确：没有母公司，也没有控股股东。也就是说，武田不存在中国公司语境下可识别的单一“实际控制人”。
Takeda is listed in Tokyo and New York and has a widely dispersed shareholder base. Its July 2026 corporate-governance report states that it has neither a parent company nor a controlling shareholder. There is therefore no identifiable individual ultimate controller in the sense commonly used for founder-controlled companies.
截至2026年6月30日，日本Master Trust Bank信托账户持有16.72%，日本Custody Bank信托账户持有5.02%，纽约梅隆银行作为ADR存托机构持有4.99%。这些多为托管或信托名义持有人，不能直接等同于最终受益人。同期外国股东合计持股48.96%，显示资本结构已经高度国际化。
As of 30 June 2026, The Master Trust Bank of Japan trust account held 16.72%, Custody Bank of Japan's trust account held 5.02%, and Bank of New York Mellon as depositary for ADR holders held 4.99%. These are largely trust or custody names and should not be treated automatically as ultimate beneficial owners. Foreign shareholders collectively held 48.96%.
治理上，董事会11人中有8名独立外部董事，董事会议长也是独立外部董事；审计监督委员会、提名与薪酬委员会均强化外部董事主导。优点是监督结构清晰，风险是所有权分散后，控制力更多集中于董事会与职业经理层，因此资本配置、激励设计和继任执行尤为关键。
Eight of the 11 directors are independent external directors, and an independent external director chairs the board. The Audit and Supervisory Committee and the nomination and compensation structures are external-director-led. Dispersed ownership makes these safeguards important: control rests mainly with the board and professional management, so capital allocation, incentives and succession execution deserve close scrutiny.
一句话总结：武田的优势是Shire并购留下的全球专科平台，变量是三款后期产品能否完成接棒，风险则是Entyvio专利周期、诉讼、杠杆与组织转型在同一窗口叠加。
Bottom line: Takeda's advantage is the global specialist platform built through Shire; the variable is whether three late-stage products can complete the relay; the risk is that Entyvio's patent cycle, litigation, leverage and organisational change converge in the same window.
互动：如果只能跟踪一个指标，你会选择三款新品的上市进度、Entyvio销售、固定汇率增长，还是净债务/EBITDA？
Question: If you could track only one metric, would it be the three launch timelines, Entyvio sales, CER growth, or adjusted net debt to EBITDA?
主要公开资料
Principal sources
Takeda Annual Integrated Report 2026及FY2025 Form 20-F；武田药品FY2026第一季度财务报告与投资者资料（2026-07-30）；公司历史、股东与2026年治理报告；Shire收购公告；NEJM发表的VARSITY与REVIVE研究；ClinicalTrials.gov的zasocitinib三期登记。公司披露的市场地位、产品收入与指引已在文中注明。资料检索截至2026-09-18 07:00。
Takeda Annual Integrated Report 2026 and FY2025 Form 20-F; Takeda FY2026 first-quarter results and investor materials dated 30 July 2026; corporate history, shareholder and 2026 governance disclosures; the Shire acquisition announcement; the VARSITY and REVIVE studies published in NEJM; and Phase 3 zasocitinib registrations on ClinicalTrials.gov. Company-reported market positions, product revenue and guidance are identified in the text. Sources were reviewed through 18 September 2026 at 07:00.
💊 关注我，每天用中英双语读懂一家药企：历史 · 产品 · 竞争 · 股权 · 风险。
💊 Follow for one bilingual pharmaceutical-company deep dive each day: history, products, competition, ownership and risk.
本文基于截至上述时点的公开资料，仅用于药学市场研究与信息交流，不构成医疗建议、诊疗依据或证券买卖建议。候选药的疗效、安全性、审评时间与商业价值均存在不确定性；投资有风险，请独立核验最新公告并评估自身风险承受能力。
This article is based on public information available at the stated time and is provided solely for pharmaceutical-market research and general information. It is not medical advice, a basis for diagnosis or treatment, or a recommendation to buy or sell securities. The efficacy, safety, review timelines and commercial value of pipeline assets remain uncertain. Independently verify the latest disclosures and assess your own risk tolerance.
并购专利到期
2026-09-14
本文由稿定助手排版，稿定助手，手机也能轻松排版！
J-Bio周报 | 日本药企每周动态速览目录前武田CEO Christophe Weber加入Rakuten Medical担任副主席第一三共在NTK 2030亿日元Fortis诉讼中胜诉中外制药3名研究人员因Hemlibra发现获Lasker奖，下一代双抗NXT007 III期临床启动筑波大学教授Yanagisawa因orexin研究获Lasker奖Elix与Axcelead DDP就靶向蛋白降解剂签署联合研究协议盐野义/StemRIM公布redasemtide两项II期临床数据卫材/渤健LEQEMBI皮下注射笔在中国获批用于早期阿尔茨海默病武田宣布R&D总裁Andrew Plump将于2027年6月退休1. 前武田CEO Christophe Weber加入Rakuten Medical担任副主席
9月9日，Rakuten Medical宣布任命前武田制药总裁兼CEO Christophe Weber为公司董事会副主席（Vice Chairman），任期自9月1日起生效。同日，前第一三共全球研发负责人Ken Takeshita加入公司董事会，加拿大籍资深肿瘤药物开发专家Hassan Danesi出任首席医学官。
Weber于2015-2026年执掌武田12年，是武田200多年历史上首位非日籍CEO，任内主导了2019年对爱尔兰夏尔（Shire）约6万亿日元的并购，使武田跻身全球前十大药企。Takeshita曾任第一三共全球研发负责人，主导了以Enhertu为代表的ADC产品线建设。
Rakuten Medical致力于开发基于Alluminox®平台的光免疫治疗（photoimmunotherapy）。其核心产品已在日本获批用于头颈癌，本次大幅强化领导层，意在加速美国监管申请与商业化。
值得关注的原因： 武田与第一三共两大日本顶级药企前核心高管同时加盟一家日本生物技术公司，反映日本生物医药产业"老兵+新平台"组合的资本运作思路；Rakuten Medical若能在美成功落地，将是日本细胞治疗/创新疗法领域少见的国际化商业案例。2. 第一三共在NTK 2030亿日元Fortis诉讼中胜诉
9月10日，第一三共宣布东京地方法院驳回Northern TK Venture Pte Ltd（NTK，IHH Healthcare的间接全资子公司）对其提起的全部损害赔偿请求，NTK需承担诉讼费用。诉讼标的额高达203,301,807,840日元（约2030亿日元/约53亿令吉），是日本制药业史上规模最大的跨境损害赔偿诉讼之一。
该诉讼源于2018年IHH通过NTK对印度Fortis Healthcare的强制公开要约收购。第一三共正依据2016年对Fortis前控股股东Singh兄弟的仲裁裁决在印度申请执行，认为NTK主张其"阻挠公开要约"的理由不成立；NTK对裁决表示"坚决不认同"，仍在评估其他法律救济手段。
值得关注的原因： 这一判决既为第一三共长期悬而未决的海外法律纠纷画上关键句号，也确认了日本法院对跨境并购纠纷的裁判立场。第一三共可将更多精力集中在ADC全球化战略上，投资者此前对此案的潜在重大损失担忧基本解除。3. 中外制药3名研究人员因Hemlibra发现获Lasker奖，下一代双抗NXT007 III期临床启动
9月10日，中外制药（Chugai）宣布其3名研究人员Tetsuya Hirata、Tatsumi Yamada、Tomoyuki Igawa因共同发现血友病A药物Hemlibra（emicizumab，艾美珠单抗）荣获Lasker-DeBakey临床医学研究奖。Hemlibra是一款FIXa×FX双特异性抗体，通过模拟凝血VIII因子的辅因子功能恢复凝血过程，自2017年获批以来已重塑血友病A治疗范式。
公司同日确认，下一代双特异性抗体NXT007（zemocimig）的全球III期ZEBRHA 2试验已于2026年4月启动，计划入组360例血友病A患者，头对头对比Hemlibra预防治疗，主要终点为治疗出血的年化出血率（ABR）。早期I/II期NXTAGE数据中，高剂量队列未观察到需治疗的出血事件，且无血栓事件。
NXT007基于Hemlibra骨架，通过FAST-Ig/ACT-Ig抗体工程平台优化半衰期和效价，目标不仅是控制出血，而是实现"接近正常人的止血状态"。
值得关注的原因： 中外制药首次同时揽获国际基础与临床领域Lasker奖，标志罗氏-中外双抗药技术平台跻身全球药学发现的最前沿；NXT007一旦III期成功，将开启"自我替代"式生命周期管理，也将巩固日本在双抗药研发上的领先地位。4. 筑波大学教授Yanagisawa因orexin研究获Lasker奖
9月10日，筑波大学教授Masashi Yanagisawa（柳沢正史，66岁）与斯坦福大学Emmanuel Mignot共同荣获Albert Lasker基础医学研究奖，表彰其在食欲素（orexin）这一调控睡眠与觉醒的关键脑肽发现上的贡献。
Yanagisawa团队1998年首次发现orexin，随后又证实orexin受体突变是小鼠嗜睡症和人类1型发作性睡病（NT1）的直接病因，为"发作性睡病本质是orexin缺乏症"的认知奠定了分子基础。其发现直接催生了OX2R激动剂类药物的开发，包括上周刚在日本获批的武田ORZEYFUL（oveporexton）。
值得关注的原因： 从基础研究到上市药物仅用约20年，是"基础研究驱动新药"的范例。Lasker奖通常被视为诺贝尔生理学或医学奖的风向标（过去约一半获奖者后续获诺奖），Yanagisawa与Mignot的获奖大幅提升NT1/嗜睡症领域的关注度，也可能带动更多食欲素通路新药开发。5. Elix与Axcelead DDP就靶向蛋白降解剂签署联合研究协议
9月9日，日本AI药物发现公司Elix（总部东京千代田区）与Axcelead Drug Discovery Partners（Axcelead DDP，总部神奈川藤泽）签署联合研究协议，共同开发靶向蛋白降解剂（TPD，包括分子胶、PROTAC等）新型发现AI技术与平台。
Elix将提供其Elix Discovery™集成AI药物发现平台（多分子生成模型+药化专家协作），Axcelead DDP则贡献分子结构信息、内部活性筛选数据和TPD研究平台。双方将通过"AI生成+湿实验验证"闭环，加快针对难以成药靶点的TPD分子发现，并拟将产生的新技术授权给全球药企与生物科技公司。
Axcelead DDP是日本首家综合性药物发现外包服务商，2017年从武田制药剥离，继承了其非临床发现平台；Elix成立于东京，专长AI药化分子设计。
值得关注的原因： PROTAC/分子胶这一新一代小分子模态（靶向"不可成药"蛋白）近年热度飙升，但分子量大、PK复杂、成药性差仍是痛点。日本罕见地把"AI+PROTAC"组合起来，并将模型-数据-实验整合，可能是日本药企在AI制药时代错位超车的一个切口。6. 盐野义/StemRIM公布redasemtide两项II期临床数据
9月9日，盐野义宣布与StemRIM联合公布"再生诱导药物"redasemtide（S-005151，一种HMGB1衍生肽，通过动员体内间充质干细胞修复组织）的两项II期临床数据：营养不良型大疱性表皮松解症（DEB）额外II期试验：3/4例难治性溃疡闭合达到主要终点，部分患者全身症状亦有改善；急性缺血性卒中（AIS）全球IIb期试验：主要终点（第90天mRS）在未接受血管内再通治疗队列未达统计学显著差异，但与既往日本II期一致地显示改善趋势，且高严重度亚组有更明显的获益倾向。
两项试验安全性良好，未发现新的安全信号。盐野义表示将进一步分析AIS数据后再决定该适应症的开发方向；DEB计划在2026财年下半年（2026年10月-2027年3月）向日本申报上市，并力争2027财年上市。
值得关注的原因： Redasemtide代表了"无细胞、通过体内干细胞动员实现组织再生"的全新模态，DEB阳性数据是这一概念在严重罕见病方向的关键验证；AIS虽未达终点，但亚组信号提示仍存在开发空间，可能影响后续适应症选择与试验设计。7. 卫材/渤健LEQEMBI皮下注射笔在中国获批用于早期阿尔茨海默病
9月3日（中国）/9月8日（美国时间），卫材与渤健宣布中国国家药品监督管理局（NMPA）批准LEQEMBI®皮下自动注射剂型（SC-AI，500 mg每周一次，分两次250 mg注射）作为早期阿尔茨海默病（MCI或轻度AD痴呆）的初始治疗。该申请于2026年1月获NMPA受理并被授予优先审评资格。
皮下注射笔单次注射约15秒，患者可居家自行给药，并在治疗期间与原有每2周一次的静脉输注灵活切换。中国是继美国之后全球第二个批准LEQEMBI SC-AI的国家，卫材预计将于其2026财年（截至2027年3月）内正式上市。
卫材估计，2024年中国MCI或轻度AD痴呆患者约1700万人，随着老龄化加剧将进一步增长。
值得关注的原因： 这是首个、也是目前唯一在中国可居家自行给药的抗淀粉样蛋白疗法，显著降低了启动与持续治疗的门槛。SC-AI相较静脉输注将大幅简化医疗机构占用、输注反应管理负担，是LEQEMBI在中美两大市场商业化加速的关键节点。8. 武田宣布R&D总裁Andrew Plump将于2027年6月退休
9月10日，武田宣布其R&D总裁Andrew Plump将于2027年6月退休。在找到继任者前，Plump将继续作为武田执行团队成员主导R&D工作。
Plump于2015年加入武田，是武田过去十余年R&D向"以转化科学和外部创新为核心"模式改革的关键推动者，先后推动了多项早期阶段外部资产引入（包括与Wave Life Sciences、Selecta Biosciences等的合作）和TAK-003、TAK-279等关键III期项目推进。
值得关注的原因： R&D总裁级人事变动通常伴随研发战略再校准，叠加武田当前在罕见病/血浆制品/神经精神等领域的关键III期读出节点，未来一年的继任者人选将直接影响武田"2030年增长愿景"的兑现路径。投资者与外部合作伙伴需关注其在并购、合作、临床优先级上的早期信号。
2026-09-10
登革病毒每周情报
2026-09-10 | 文献与公共卫生新闻
文献：检索840｜日期窗793｜去重203｜终审62｜主报告46｜补充16
新闻：检索184｜日期窗184｜主新闻7｜补充74
📚 本期文献进展
本期登革病毒研究集中呈现以下进展。
70% 的儿童入院时出现 重症登革热 休克,58.8% 的儿童出现多器官功能障碍。82.4% 的病例中发现了可改变的因素,包括延迟识别代偿性休克和液体管理问题。 [10.1007/s12098-026-06434-z]。
患者登革热IgM检测呈阳性,伴有血小板减少(104,000/mm3)和肝酶升高。影像学检查确认了肝静脉血栓形成、下腔静脉狭窄和尾状叶增大,确立了诊断与布-奇亚里综合征的关联。血栓形成倾向筛查显示蛋白C、蛋白S和抗凝血酶III缺乏。患者还出现了严重的双下肢疼痛,神经传导研究证实了双下肢的感觉性多发性神经病。
ZIKV 感染产生持续的 NS1 反应,而原发性 DENV 感染表现出最小的 ZIKV 交叉反应性,继发性 DENV 感染仅表现出短暂的、低水平的增加。 [10.64898/2026.09.04.26362297]。
在260名参与者中,78名(30.0%)检测出登革热血清学阳性,182名(70.0%)检测为阴性。发热是最常见的症状,有157名(60.38%)参与者报告了发热。大多数参与者未住院,229名(88.08%),248名(95.38%)存活,记录到12名(4.62%)死亡。
📰 本期新闻动态
本期登革病毒新闻集中呈现以下动态。
世卫组织举办名为"Shastho Chorcha"的对话,以强调在登革热应对中采取政府与社会整体行动。这是世界卫生组织的官方声明。 [news-a459e551765b40c5]。
The World Health Organization (WHO) has identified six dengue drug candidates with evidence warranting further development, with only VIS513 reaching Phase 3 trials.
菲律宾卫生部记录了2026年8月2日至15日的15,763例登革热病例,比前一个两周时期(2026年7月19日至8月1日)增加了9%。 [news-f53ad522c85c7218]。
佛罗里达州正经历登革热病例激增,佛罗里达州卫生部尚未确认诊断及死亡病例,但这种情况似乎预示着该州可能面临严峻的公共卫生挑战。该事件由坦帕湾时报和Jezebel报道,盖伊·斯莫尔这位80岁女性的死亡被怀疑为本地传播病例。📘 主报告文献
Journal: Bioorganic chemistry | Canonical publication date: 2026-09-06 | DOI: 10.1016/j.bioorg.2026.110485
A 高优先级学术文献 · 综述作为 抗病毒药物 药物开发靶标的 登革病毒 NS2B-NS3 蛋白酶的结构生物学。
Structural biology of the dengue virus NS2B-NS3 protease as a target for antiviral drug development.
Authors: Rahit Paul, Deeti Jyothi, Maitreyee Mukherjee, Srijita Chatterjee, Priya Manna, Purna Chandra Pal, Maytree Mukerjee, Srijita Chaterjee
摘要中文翻译登革热是近年来最常见的全球性问题,特别是在热带和亚热带地区,但目前缺乏治疗或预防的抗病毒药物。数百万人受到这种 登革病毒 的影响,但目前还没有适当的药物来治愈这种疾病。DENV 基因组 编码的一种多蛋白被转化为病毒 发病机制 和复制所必需的结构和非结构蛋白。其中,非结构蛋白复合物 NS2B-NS3 对于病毒多蛋白加工、复制和 宿主 固有的 免疫应答 控制至关重要。它充当胰蛋白酶样丝氨酸蛋白酶。NS2B/NS3 蛋白酶是参与病毒复制的关键酶,是针对 登革病毒 药物开发的主要靶标。NS3 蛋白酶具有保守的催化三联体 (His-Asp-Ser),而 NS2B 是稳定酶活性构象并有助于底物识别的重要辅助因子。通过破坏干扰素信号通路,NS2B-NS3 蛋白酶不仅有助于病毒复制,还使免疫逃避变得更容易。抑制这种酶作用的化合物可能是 抗病毒药物 药物发现过程的先驱。本文全面概述了病毒蛋白酶 (NS2B/NS3) 酶的详细结构信息以及该酶的作用机制,并重点介绍了与 NS2B/NS3 蛋白酶相关的各种抑制剂。更彻底地理解这种蛋白酶可以促进有效的 抗病毒药物 药物的逻辑开发,以预防登革热感染。
综述五要素范围与问题该综述重点关注 登革病毒 NS2B-NS3 蛋白酶的结构生物学,特别是其在病毒复制中的作用以及作为 抗病毒药物 药物开发靶标的作用。核心问题是了解蛋白酶的结构和功能如何有助于创建针对登革热感染的有效 抗病毒药物 疗法。证据基础与方法该综述是对 登革病毒 中 NS2B-NS3 蛋白酶的结构和功能方面的全面分析。它不报告特定数据库、检索日期或研究资格标准。该评论主要是叙述性的,总结现有的知识,没有详细说明荟萃分析或共识过程。共识与结论NS2B-NS3 蛋白酶是 登革病毒 复制的关键酶,对于加工病毒多蛋白至关重要。它作为胰蛋白酶样丝氨酸蛋白酶发挥作用,并在调节 宿主 固有 免疫应答 中发挥关键作用。该蛋白酶的保守催化三联体 (His-Asp-Ser) 以及 NS2B 作...争议与缺口该综述强调,虽然 NS2B-NS3 蛋白酶是药物开发的关键靶点,但有关免疫逃避的具体机制以及蛋白酶在不同 登革病毒 血清型中的精确作用的信息有限。此外,该综述并未涉及跨血清型抑制的潜力或体内抑制剂的有效性。科研与实践启示需要进一步的研究来探索 NS2B-NS3 蛋白酶在 登革病毒 血清型之间的结构变异,并开发对所有血清型有效的抑制剂。还需要进行体内研究来评估针对该蛋白酶的潜在 抗病毒药物 化合物的功效和安全性。此外,了解蛋白酶在免疫逃避中的作用可能会导致...
Journal: Pediatric radiology | Canonical publication date: 2026-09-05 | DOI: 10.1007/s00247-026-06771-3
A 高优先级学术文献 · 综述小儿登革热中枢神经系统感染的不同神经放射学表现:来自巴基斯坦的图片回顾与文献相关性。
The varying neuroradiological manifestations of pediatric dengue central nervous system infection: a pictorial review from Pakistan with literature correlation.
Authors: Kumail Khandwala, Syed Mohammad Hasan, Sahra Khan Mateen, Naila Nadeem, Kiran Hilal
摘要中文翻译登革热感染是儿童神经系统并发症的一个日益被认识的原因,其累及中枢和周围神经系统的范围广泛且不断演变。这篇图片综述使用基于病理生理学和成像模式的方法系统地说明了儿科登革热的神经放射学表现,并将特征性磁共振成像 (MRI) 结果与当前文献相关联。神经影像学表现大致分为直接病毒神经侵袭性、免疫介导性和可逆性水肿模式。病毒直接累及包括脑膜脑炎、深部灰质累及和菱形脑炎,严重病例表现出坏死性脑病样脑炎的特征性“双甜甜圈”征象和脑桥受累的“南瓜灯”征象。免疫介导的白质损伤包括扩散受限的急性白质脑病和急性播散性脑脊髓炎,它们的扩散特征和与感染的时间关系不同。可逆性水肿综合征包括可逆性压部病变综合征和较少报道的可逆性后部脑病综合征,两者都与良好的临床和放射学结果相关。脊髓和周围神经系统表现包括脊髓炎和吉兰-巴利综合征,MRI 在区分这些实体与其他感染性和炎症性脊髓神经根病方面发挥着关键作用。重要的是,磁敏感加权或梯度回忆回波成像的病灶内出血性变化,特别是在深灰核和脑干内,代表了一种有价值的成像标记,有利于登革热而不是几种病毒和炎症模拟物。识别这些基于特征模式的神经放射学表现及其潜在的病理生理学相关性可...
综述五要素范围与问题登革热感染是儿童神经系统并发症的一个日益被认识的原因,其累及中枢和周围神经系统的范围广泛且不断演变。证据基础与方法这篇图片综述使用基于病理生理学和成像模式的方法系统地说明了儿科登革热的神经放射学表现,并将特征性磁共振成像 (MRI) 结果与当前文献相关联。共识与结论可逆性水肿综合征包括可逆性压部病变综合征和较少报道的可逆性后部脑病综合征,两者都与良好的临床和放射学结果相关。争议与缺口重要的是,磁敏感加权或梯度回忆回波成像的病灶内出血性变化,特别是在深灰核和脑干内,代表了一种有价值的成像标记,有利于登革热而不是几种病毒和炎症模拟物。科研与实践启示识别这些基于特征模式的神经放射学表现及其潜在的病理生理学相关性可以提高诊断信心,促进与竞争性诊断的区分,并指导流行地区儿科登革热神经系统疾病的及时管理。
Journal: medRxiv | Canonical publication date: 2026-09-08 | DOI: 10.64898/2026.09.04.26362297
A 高优先级学术文献 · 研究应用多重电化学发光 NS1 测定法检测和区分巴西和泰国 队列研究 长期社区中的寨卡病毒和 登革病毒 暴露情况
Applying a multiplex electrochemiluminescence NS1 assay to detect and differentiate Zika and dengue virus exposures in long-term community cohorts in Brazil and Thailand
Authors: Nivison Nery, Marco Hamins-Puertolas, Lauren Bahr, Jaqueline S. Cruz, Joseph Lu, M. Catherine Muenker, Juan P. Aguilar Ticona, Ruchira Khosavanna, Mariam O. Fofana, Oliveira Dd
摘要中文翻译背景:由于抗原交叉反应,区分寨卡病毒 (ZIKV) 和 登革病毒 (DENV) 感染仍然是共流行地区的主要诊断挑战。我们评估了多重电化学发光 Meso Scale Discovery System (MSD) NS1 检测,以在不同免疫背景下高度特异性地定义 ZIKV 感染。方法:我们分析了多个 队列研究 中经 PCR 确认的 ZIKV 和 DENV 感染的纵向样本,评估了 MSD NS1 信号强度和 PRNT50 滴度之间的相关性,并进行了 ROC 分析以得出血清转化阈值。然后,我们应用这些标准来确定巴西(2015-2024 年)和泰国(2015-2025 年)的 ZIKV 血清转化情况。研究结果:ZIKV 感染产生持续的 NS1 反应,而原发性 DENV 感染表现出最小的 ZIKV 交叉反应性,继发性 DENV 感染仅表现出短暂的、低水平的增加。MSD NS1 信号强度与 ZIKV 和所有四种 DENV 血清型的 PRNT50 滴度相关 (rho = 0.54-0.84)。ROC 分析确定,最佳 ZIKV 血清转换截止值至少为 10.96 倍数变化,未接触过 DENV 的参与者的...
研究七要素问题与背景由于抗原交叉反应,区分寨卡病毒 (ZIKV) 和 登革病毒 (DENV) 感染仍然是共流行地区的主要诊断挑战。设计与对象我们分析了多个 队列研究 中经 PCR 确认的 ZIKV 和 DENV 感染的纵向样本,评估了 MSD NS1 信号强度和 PRNT50 滴度之间的相关性,并进行了 ROC 分析以得出血清转化阈值。核心方法然后,我们应用这些标准来确定巴西(2015-2024 年)和泰国(2015-2025 年)的 ZIKV 血清转化情况。主要结果ZIKV 感染产生持续的 NS1 反应,而原发性 DENV 感染表现出最小的 ZIKV 交叉反应性,继发性 DENV 感染仅表现出短暂的、低水平的增加。解释与创新MSD NS1 多重检测提供了一种可扩展、定量和高度特异性的方法,用于识别 ZIKV 感染并估计共流行环境中的血清发生率。科研与公卫意义双阈值框架(倍数变化至少 10.96 且 ZIKV/DENV 比率 > 1)提高了诊断精度,为黄病毒流行地区的 监测 和 传播 研究提供了强大的工具。局限与证据强度ROC 分析确定,最佳 ZIKV 血清转换截止值至少为 10.96 倍数变化,未接触过 DENV 的参与者的 AUC 为 100%,暴露于 DENV 的参与者的 AUC 为 90.7%。
Journal: Research Square | Canonical publication date: 2026-09-08 | DOI: 10.21203/rs.3.rs-10942592/v1
A 高优先级学术文献 · 综述评估登革热病毒血症作为登革热 抗病毒药物 III 期试验替代疗效结果的适用性:系统评价
Evaluating the Suitability of Dengue Viraemia as a Surrogate Efficacy Outcome for Phase III Trials of Dengue Antivirals: A Systematic Review
Authors: Jeslyn Gonsalves, Yan Naung Win, Elinor Harriss, Richard J. Maude, Xin Hui S Chan, Elinor Harris
摘要中文翻译摘要背景:随着地域扩张到欧洲和非洲,登革热病例在 2024 年达到创纪录水平。重症登革热 的低进展率对登革热 III 期 抗病毒药物 试验的支持提出了挑战。病毒血症在 II 期试验中被用作病毒学结果,但 治疗 诱导的减少是否可靠地预测临床益处仍不确定。这项系统评价评估了登革热病毒血症与疾病严重程度之间的关联及其作为 III 期 抗病毒药物 试验的替代疗效结果的适用性。方法:我们于 2025 年 6 月 20 日检索了 Ovid MEDLINE、Ovid Embase、Scopus 和 Web of Science,查找自 2017 年以来编入索引的研究,扩展了之前的系统评价。我们纳入了实验室确诊的登革热临床研究,在入组时和至少一个后续时间点通过 RT-PCR 测量定量血清病毒载量,并报告 重症登革热 作为临床结果。该审查已在 PROSPERO 注册 (CRD420251077148),并遵循 PRISMA 2020 报告指南。结果:筛选3303条记录,审阅全文60篇;11 项研究符合纳入标准,主要包括来自亚太地区的住院儿童和年轻成人 队列研究。七项研究报告称,病情较严重的患者早期病毒...
综述五要素范围与问题登革病毒 1-4 和登革热病;其他黄病毒属于近邻排除项。生物相关的动物、分类学、模型、差异-诊断 和比较实体仅是补充,除非还存在材料目标特定证据;只有显式的词汇或不相关的硬排除才是最终的。证据基础与方法我们于 2025 年 6 月 20 日在 Ovid MEDLINE、Ovid Embase、Scopus 和 Web of Science 中检索了自 2017 年以来编入索引的研究,扩展了之前的系统综述。该审查已在 PROSPERO 注...共识与结论登革热病毒血症与疾病严重程度之间关联的证据不一致,并且受到方法学异质性的限制。证据的质量非常低。争议与缺口采样时间、严重程度分类以及 宿主 和病毒因素调整的异质性限制了解释。大多数研究在入院时评估严重程度,无法确定病毒血症是否可以预测随后从非严重疾病进展为严重疾病。科研与实践启示没有一个旨在确定 治疗 诱导的病毒血症减少是否转化为临床益处。因此,登革热病毒血症应被视为早期 抗病毒药物 开发的药效生物标志物和支持性病毒学结果,而不是作为 III 期试验的经过验证的替代疗效结果,因为 III 期试验仍需要具有临床意义...
Journal: Annals of African medicine | Canonical publication date: 2026-09-09 | DOI: 10.4103/aam.aam_503_26
A 高优先级学术文献 · 研究超越出血:一例急性登革病毒感染伴发布-奇亚里综合征和双侧感觉性多发性神经病的病例
Beyond Hemorrhage: A Case of Acute Dengue Infection Presenting with Budd-Chiari Syndrome and Bilateral Sensory Polyneuropathy.
Authors: Krushna Keshav Dalvi, Priya Khaire, Mohammed Hassan Shaik
摘要中文翻译摘要 布加综合征 (BCS) 是一种罕见的肝血管疾病,其特征是肝静脉流出道阻塞,每年每百万人口中有 1-2 例出现 发病率。虽然 登革热 主要与出血并发症相关,但血栓事件却很少报道。据我们所知,这是第一个有记录的与 登革热 相关的 BCS 病例。一名22岁农村男性因腹痛、发热、呕吐、稀便病史4天就诊。体检发现肝肿大、腹水和轻度脱水。实验室检查证实登革热 IgM 阳性,伴有血小板减少 (104,000/mm 3 ) 和肝酶升高。血栓形成倾向筛查显示蛋白 C、蛋白 S 和抗凝血酶 III 缺乏。影像学研究,包括超声检查、对比计算机断层扫描和彩色多普勒,显示肝静脉血栓形成、下腔静脉狭窄和尾状叶肥大,建立了 BCS 的 诊断。上消化道内镜检查显示II级食管静脉曲张,符合门静脉高压症。入院期间,患者还出现双下肢严重疼痛,强效镇痛药无效,神经传导检查证实双下肢存在感觉性多发性神经病。该患者接受了支持性护理和使用低分子肝素 (LMWH) 的仔细抗凝治疗,随后每天服用 4 mg 华法林。尽管最初出现血小板减少,但通过密切监测出血并发症,成功开始抗凝治疗。该患者表现出良好的临床反应,随访时肝静脉血栓完...
研究七要素问题与背景本研究旨在记录一种罕见且新颖的关联,即登革热与布-奇亚里综合征(BCS)及双侧感觉性多发性神经病之间的联系,强调识别登革病毒感染非典型表现的重要性。设计与对象对一名22岁男性患者进行单病例研究,该患者来自农村地区,表现为急性登革病毒感染,伴有腹痛、发热、呕吐和腹泻,同时出现布-奇亚里综合征和感觉性多发性神经病的体征。核心方法通过实验室检查,包括登革热IgM检测、血小板减少评估和肝酶升高,确认了患者的诊断。利用超声检查、增强型计算机断层扫描和彩色多普勒成像评估肝静脉流出道阻塞。进行了血栓形成倾向筛查以评估凝血因子。主要结果患者登革热IgM检测呈阳性,伴有血小板减少(104,000/mm3)和肝酶升高。影像学检查确认了肝静脉血栓形成、下腔静脉狭窄和尾状叶增大,确立了诊断与布-奇亚里综合征的关联。血栓形成倾向筛查显示蛋白C、蛋白S和抗凝血酶III缺乏。患者还出...解释与创新作者将此病例解释为首次记录的布-奇亚里综合征与登革热相关联的病例,强调了短暂性血栓形成倾向以及布-奇亚里综合征与双侧感觉性多发性神经病的不寻常组合。科研与公卫意义该病例为登革病毒感染的非典型临床表现提供了重要见解,特别是与布-奇亚里综合征和感觉性多发性神经病的关联,这可能有助于更广泛的监测和登革热相关并发症的诊断方法。局限与证据强度该研究仅限于单个 病例报告,可能无法推广。然而,证据是强有力的,因为它包括详细的临床、实验室和影像学结果,支持 BCS 的 诊断 和 登革热,并具有明确的时间关系。
Journal: Open Research Africa | Canonical publication date: 2026-09-08 | DOI: 10.12688/openresafrica.16780.1
A 高优先级学术文献 · 研究临床特征、相关因素、治疗行为及Las’anod,Sool地区索马里成年急性发热病例中登革热的结局:一项基于医院的横断面研究
Clinical Characteristics, Associated Factors, Treatment Practices, and Outcomes of Dengue Fever among Adult Acute Febrile Illness Cases in Las’anod, Sool Region, Somalia: A Hospital-Based Cross-Sectional Study
Authors: Mohamed ja, Ahmed Farah Darod2*, Fufa Miresa Benti, Jama Abdiaziz Mohamed
摘要中文翻译背景:登革热是索马里新兴的公共卫生问题,但关于其在成年急性发热病例中的临床表现、血清学检测模式、相关因素、治疗行为及结局的证据仍有限。本研究评估了Las’anod,Sool地区索马里成年急性发热病例中的登革热情况。方法:在Las’anod综合医院、Manhal医院和索马里高级医院中,对260名被评估为登革热的成年急性发热患者进行了基于医院的横断面研究。数据通过标准化的数据提取清单从患者记录、临床评估表和实验室记录中收集。通过血清学检测结果确定登革热阳性。分析使用了描述性统计、卡方检验、二元逻辑回归和多变量逻辑回归。报告了调整后的比值比及其95%置信区间,统计学显著性设定为p < 0.05。结果:在260名参与者中,78名(30.0%)检测出登革热血清学阳性,182名(70.0%)检测为阴性。阳性病例中,61名(23.5%)仅IgM阳性,17名(6.5%)同时IgM和NS1阳性。发热是最常见的症状,有157名(60.38%)参与者报告了发热。大多数参与者未住院,229名(88.08%),248名(95.38%)存活,记录到12名(4.62%)死亡。在多变量分析中,年龄25–35岁、家庭...
研究七要素问题与背景登革热是索马里新兴的公共卫生问题,但关于其在成年急性发热病例中的临床表现、血清学检测模式、相关因素、治疗行为及结局的证据仍有限。本研究评估了Las’anod,Sool地区索马里成年急性发热病例中的登革热情况。设计与对象在Las’anod综合医院、Manhal医院和索马里高级医院中,对260名被评估为登革热的成年急性发热患者进行了基于医院的横断面研究。核心方法数据通过标准化的数据提取清单从患者记录、临床评估表和实验室记录中收集。分析使用了描述性统计、卡方检验、二元逻辑回归和多变量逻辑回归。通过血清学检测结果确定登革热阳性。主要结果在260名参与者中,78名(30.0%)检测出登革热血清学阳性,182名(70.0%)检测为阴性。发热是最常见的症状,有157名(60.38%)参与者报告了发热。大多数参与者未住院,229名(88.08%),248名(95.38%)存活,...解释与创新在多变量分析中,年龄25–35岁、家庭月收入、既往登革热诊断、知识水平和室内储水显著与登革热阳性相关。科研与公卫意义加强登革热诊断、社区意识、安全储水行为、媒介控制及标准化临床管理可能有助于提高在资源有限环境中的检测、预防和治疗效果。局限与证据强度所提供的证据并未报告局限性或证据强度。
Journal: Virulence | Canonical publication date: 2026-09-08 | DOI: 10.1080/21505594.2026.2721757
A 高优先级学术文献 · 研究一种肠道共生菌施氏假单胞菌通过产色菌素诱导的自噬抑制登革病毒感染
A gut commensal Serratia marcescens inhibits dengue virus infection via prodigiosin-induced autophagy in Aedes albopictus .
Authors: Yijia Huang, Hongbo Li, Jinying Ding, Yihan Zhu, Nan Wang, Jiawei Zhang, Haojie Wang, Xiao Feng, Haodong Xu, Wenquan Liu
摘要中文翻译蚊虫肠道微生物群在调节虫媒病毒传播中起着关键作用,但其原生共生菌产生的特定抗病毒药物代谢产物及其潜在机制仍不清楚。本研究从中国温州地区捕获的Aedes albopictus中分离出一种天然肠道共生菌Serratia marcescens WZ1菌株,并证明其对登革病毒(登革病毒DENV)感染具有显著的抑制作用。通过整合代谢组学分析,我们鉴定了该菌株分泌的一种红色色素产色菌素(PG)作为功能性抗病毒药物代谢产物。PG在剂量和时间依赖性实验中显著抑制了蚊虫细胞中的DENV感染,并显著降低了成年Ae. albopictus中的DENV2 RNA水平。机制研究显示,PG优先定位于内质网(ER),诱导ER应激并上调伴侣蛋白GRP78的表达。这一过程随后激活了完整的自噬通量,表现为Atg8-I向Atg8-II的转化增强、自噬体形成增加以及溶酶体活性升高。重要的是,我们进一步证明PG促进了自噬体与溶酶体的融合,导致登革病毒与溶酶体区室共定位并最终被清除。通过基因敲低自噬基因Atg8和药理学抑制ER应激,显著减弱了PG介导的病毒抑制作用,证实了PG诱导的ER应激、自噬激活与病毒清除之间的功能联系。我...
研究七要素问题与背景本研究旨在探讨蚊虫肠道微生物群在调节虫媒病毒传播中的作用,重点在于鉴定特定的抗病毒药物代谢产物及其对抗登革病毒的机制。设计与对象本研究从中国温州地区捕获的Aedes albopictus中分离出Serratia marcescens WZ1菌株,并展示了其抑制登革病毒感染的能力。研究使用了蚊虫细胞和成年Ae. albopictus进行。核心方法研究人员通过整合代谢组学分析鉴定了Serratia marcescens WZ1菌株分泌的抗病毒药物代谢产物产色菌素(PG)。他们通过剂量和时间依赖性实验评估了PG对登革病毒感染的影响,并进行了机制研究以确定其对ER应激、自噬激活和病毒清...主要结果PG在剂量和时间依赖性实验中显著抑制了蚊虫细胞中的登革病毒感染,并显著降低了成年Ae. albopictus中的DENV2 RNA水平。机制研究显示,PG诱导ER应激并上调GRP78,从而引发自噬通量。PG还促进了自噬体与溶酶体的融合,导...解释与创新这些发现揭示了一种原生蚊虫肠道共生菌代谢产物通过激活宿主 ER应激-自噬通路抑制虫媒病毒感染的新机制,为未来传播阻断策略提供了机制基础。科研与公卫意义这些结果为利用肠道微生物群衍生代谢产物开发新的阻断虫媒病毒登革病毒和传播的策略提供了见解,可能有助于未来关于监测、诊断以及干预措施的研究。局限与证据强度本研究的证据较强,因为它包括机制研究和剂量依赖性结果,但其研究局限于蚊虫细胞和成年Ae. albopictus的体外和体内实验,可能无法完全反映自然传播动态。
Journal: In silico pharmacology | Canonical publication date: 2026-09-06 | DOI: 10.1007/s40203-026-00738-w
A 高优先级学术文献 · 研究DrugBank小分子药物针对登革病毒衣壳蛋白的再利用:一项计算机模拟研究。
Repurposing of DrugBank small molecules against Dengue virus capsid protein: an in silico study.
Authors: Dwaipayan Chaudhuri, Kalyan Giri
摘要中文翻译未标注:登革病毒(登革病毒)仍然是一个紧迫的全球健康威胁,目前尚无批准的抗病毒药物治疗方法。本研究探讨了登革病毒衣壳蛋白二聚体界面处的保守疏水口袋作为新型抗病毒药物干预靶点。我们使用高分辨率衣壳结构(包含建模的N端无序区域)对DrugBank数据库进行了虚拟筛选,以识别潜在的可再利用抑制剂。根据对接评分和结合位点特异性,筛选出六个最佳结合候选分子。这些分子随后接受了经典分子动力学(MD)模拟以评估复合物的稳定性,并通过热滴定分子动力学(TTMD)评估其在热应激下的相互作用稳定性。三种分子(DB02152、DB08683和DB13014)在MD和TTMD分析中表现出高度稳定的结合,其中DB13014(Hypericin)显示出最高的热稳定性和有利的相互作用能量。计算机模拟的ADMET分析进一步验证了这些化合物的药物特性,表明其口服生物利用度可接受、毒性风险低且易于合成。这些发现突显了登革病毒衣壳蛋白疏水口袋作为可行的药物靶点,并提出了小分子药物再利用作为抗登革热治疗的可能性。补充信息:在线版本包含可在https://doi.org/10.1007/s40203-026-00738-w获...
研究七要素问题与背景登革病毒(登革病毒)仍然是一个紧迫的全球健康威胁,目前尚无批准的抗病毒药物治疗方法。本研究旨在识别针对登革病毒衣壳蛋白的潜在可再利用抑制剂。设计与对象本研究是一项计算机模拟调查,探讨登革病毒衣壳蛋白二聚体界面处的保守疏水口袋。该研究使用包含建模的N端无序区域的高分辨率衣壳结构对DrugBank数据库进行虚拟筛选。核心方法使用包含建模的N端无序区域的高分辨率衣壳结构,我们通过AutoDock Vina对DrugBank数据库进行了虚拟筛选,以识别潜在的可再利用抑制剂。根据对接评分和结合位点特异性,筛选出六个最佳结合候选分子。这些分子随后接受了经典分子动力学...主要结果三种分子(DB02152、DB08683和DB13014)在MD和TTMD分析中表现出高度稳定的结合,其中DB13014(Hypericin)显示出最高的热稳定性和有利的相互作用能量。计算机模拟的ADMET分析进一步验证了这些化合物的药物...解释与创新这些发现突显了登革病毒衣壳蛋白疏水口袋作为可行的药物靶点,并提出了小分子药物再利用作为抗登革热治疗的可能性。本研究引入了一种新颖的方法,通过关注衣壳蛋白的结构特征来识别潜在的抑制剂。科研与公卫意义这些结果为这些化合物作为抗登革热治疗的进一步实验验证提供了基础,为药物开发提供了潜在的先导化合物。这可能为未来关于现有药物再利用用于登革热治疗的研究提供信息。局限与证据强度本研究仅限于计算机模拟方法,可能无法完全反映体内条件。由于研究结果基于计算模型,证据强度中等,需要实验验证。
Journal: Bangladesh Journal of Infectious Diseases | Canonical publication date: 2026-09-08 | DOI: 10.3329/bjid.v13i1.85062
A 高优先级学术文献 · 综述登革病毒患病率、暴发病毒复制、诊断、治疗、媒介控制及预防策略:全面综述
Insights into Dengue Prevalence, Outbreaks, Virus Replication, Diagnosis, Treatment, Vector Control, and Preventive Strategies: A Comprehensive Review
Authors: Nizam Uddin, Md. Shahadat Bin Shahid, Anika Tasnim
摘要中文翻译
综述五要素范围与问题Dengue virus (DENV), a mosquito-borne RNA virus of the Flaviviridae family, poses a major global health challenge, with...证据基础与方法本综述对登革病毒的流行病学、病毒传播动力学、复制机制、临床表现和诊断方法进行了全面分析。它主要通过伊蚊传播,特别是埃及伊蚊(Aedes aegypti)和白纹伊蚊(Aedes albopictus),这些蚊子在热带和亚热带地区繁衍生息。该...共识与结论登革病毒的传播增加是由气候变化、城市化以及防控措施不足所驱动的,南亚、美洲和东南亚等地区每年报告数百万例病例。争议与缺口尽管在疫苗研究方面做出了努力,但媒介控制仍然是登革热预防的主要策略,重点在于环境管理、生物控制和有针对性的化学干预。研究结果强调了在全球范围内加强监测系统、整合媒介管理以及开展公共卫生举措的迫切需求。科研与实践启示增强诊断能力、扩大疫苗接种计划并投资于创新的蚊媒控制策略,对于减轻登革热日益增长的负担至关重要。
Journal: Research Square | Canonical publication date: 2026-09-04 | DOI: 10.21203/rs.3.rs-10328635/v1
A 高优先级学术文献 · 研究资源匮乏地区急性登革热相关心肌炎病例系列:来自科特迪瓦的案例
Acute Dengue-associated Myocarditis in a Resource-limited Setting: A Case Series From Côte D'ivoire
Authors: Ines Angoran Regnier, Adama Doumbia, Corinne Akpovo, Roland N’guetta, Christophe Konin, Serge Paul Eholie, Serge Eholié
摘要中文翻译摘要 登革热相关综合征可进展为严重的器官功能障碍。在其中不典型的并发症中,急性心肌炎罕见、诊断不足且可能致命。我们报告了四例年轻男性患者在阿比让的特里奇维尔大学医院(科特迪瓦)入院,展示了与登革热相关的心肌炎多样临床表现。临床表现从急性心力衰竭到需要临时经静脉起搏的高危房室传导阻滞不等,这些情况发生在登革热病程的不同阶段。尽管高敏肌钙蛋白升高是一致的预警信号,但3特斯拉心脏磁共振成像(CMR)通过局部水肿和心外膜下晚期钆增强明确确认了心肌炎症。该病例系列强调了在登革热 暴发 中对心肌炎保持高度临床怀疑的重要性,因为其管理需要在补液和心肌负担之间进行谨慎平衡。
研究七要素问题与背景本研究旨在解决与登革热相关且可能致命的急性心肌炎这一未被充分诊断的并发症。研究强调了在登革热 暴发 期间识别这一罕见状况的重要性。设计与对象本研究是一项病例系列研究,报告了四例年轻男性患者在阿比让的特里奇维尔大学医院入院,他们在登革热病程的不同阶段表现出急性心肌炎。该人群包括因心肌炎作为并发症而患病的登革热感染者。核心方法本研究包括对患者的临床评估,使用高敏肌钙蛋白检测和3特斯拉心脏磁共振成像(CMR)来通过局部水肿和心外膜下晚期钆增强确认心肌炎症。这些方法用于评估临床表现并确认登革热相关心肌炎的 诊断。主要结果患者表现出一系列症状,从急性心力衰竭到需要临时经静脉起搏的高危房室传导阻滞。高敏肌钙蛋白水平在所有病例中均一致升高,3特斯拉CMR成像在所有病例中均明确确认了心肌炎症。解释与创新作者认为,这些病例强调了在登革热 暴发 期间对心肌炎保持高度临床怀疑的必要性,因为其管理需要在补液和心肌负担之间进行谨慎平衡。该病例系列提供了关于登革热相关心肌炎多样化临床表现的新见解。科研与公卫意义这些发现可以为登革热相关心肌炎的诊断和治疗实践提供改进的依据,特别是在资源匮乏的环境中,并强调及时和适当的管理策略对于预防严重后果的重要性。局限与证据强度该研究受限于样本量小和缺乏对照组,这可能影响研究结果的普遍适用性。然而,该病例系列提供了关于登革热相关心肌炎临床表现范围的重要见解,支持中等程度的置信度评估。
Journal: International journal of biological macromolecules | Canonical publication date: 2026-09-04 | DOI: 10.1016/j.ijbiomac.2026.154293
A 高优先级学术文献 · 研究基于生物发光的直接作用 登革病毒 NS5 甲基转移酶抑制剂的高通量筛选和鉴定。
Bioluminescence-based high-throughput screening and identification of direct-acting dengue virus NS5 methyltransferase inhibitors.
Authors: Chenchen Li, Jianfang Zhang, Yuegao Hu, Yanyang Su, Ni Liu, Zhang Zhang, Qinhai Ma, Zifeng Yang, Yingjun Li
Journal: bioRxiv (Cold Spring Harbor Laboratory) | Canonical publication date: 2026-09-04 | DOI: 10.64898/2026.09.02.748787
A 高优先级学术文献 · 研究登革热 NS2B-NS3 蛋白酶结构动力学的实验和计算机分析
Experimental and In Silico Analysis of the Structural Dynamics of Dengue NS2B-NS3 Protease
Authors: Susmida Seni Balakrishnan, SIVARAMAN MANJINI, Dhina S, KSHIRABDHI DHAL, Shibangi Das, Suresh Kumar Muthuvel
Journal: Indian journal of pediatrics | Canonical publication date: 2026-09-09 | DOI: 10.1007/s12098-026-06434-z
A 高优先级学术文献 · 研究儿科病例登革热死亡审计:三级护理中心的临床分析。
Dengue Death Audit in Pediatric Cases: A Clinical Analysis from a Tertiary Care Centre.
Authors: Raghavendra G. Namadhari, Vinod H. Ratageri, Madhu P K, Shivanand Illalu, Siddappa F Dandinavar, Harish Sheri, Raghavendra G Namadhari, Vinod H Ratageri, Namadhari RG, Ratageri VH
Journal: Interdisciplinary perspectives on infectious diseases | Canonical publication date: 2026-09-06 | DOI: 10.1155/ipid/4901627
A 高优先级学术文献 · 综述在登革热高风险工业区建立无登革热工厂评估框架的主动举措:叙述性审查。
Proactive Initiative to Establish a Dengue-Free Factory Assessment Framework in Dengue High-Risk Industrial Areas: A Narrative Review.
Authors: Wanapa Ritthison, Adisak Bhumiratana, Chanthana Padungtod, Narongsak Tongtummachart
Journal: medRxiv | Canonical publication date: 2026-09-07 | DOI: 10.64898/2026.09.03.26362163
A 高优先级学术文献 · 研究模拟 2018 年至 2024 年间厄尔尼诺南方涛动 (ENSO) 对阿根廷登革热 暴发 动态的影响。
Modelling the impact of the El Nino Southern Oscillation (ENSO) on the dynamics of Dengue outbreaks in Argentina between 2018 and 2024.
Authors: Chiara Lodigiani, Alejandro Enet, Maia Arrua, Gabriela Lakkis, Lucas Moreno Lell, Carla Panzarella, Sol Otero, Ornella Bellizzi, Bullo, M., Perez-Lloret, S.
Journal: Tropical Medicine and Infectious Disease | Canonical publication date: 2026-09-08 | DOI: 10.3390/tropicalmed11090252
A 高优先级学术文献 · 综述儿童 重症登革热:重症登革热、早期识别和循证管理
Severe Dengue in Children: Pathogenesis, Early Recognition, and Evidence-Informed Management
Authors: Hsien-Yi Wang, Shih-Bin Su, Chung‐Yi Li, Kow‐Tong Chen
Journal: Journal of Umm Al-Qura University for Applied Sciences | Canonical publication date: 2026-09-08 | DOI: 10.1007/s43994-026-00328-8
A 高优先级学术文献 · 研究印度尼西亚马塔兰城市高 发病率 地区循环 登革病毒 血清型的分子检测和空间分布(2024-2025 年)
Molecular detection and spatial distribution of circulating dengue virus serotypes in an urban high-incidence area of Mataram, Indonesia (2024–2025)
Authors: Raodatul Jannah, Sitti Rahmah Umniyati, Tri Baskoro Tunggul Satoto, Nur Alvira Pascawati, Muhammad Sopian Sauri, Imran Sadewo, Hilmi Hidayati, Rizal M. Suhardi, Sais Sularsah
Journal: Scientific Reports | Canonical publication date: 2026-09-05 | DOI: 10.1038/s41598-026-69896-3
A 高优先级学术文献 · 研究使用具有基于块的序列建模和可解释性分析的 Transformer 从完整的 基因组 中进行 登革病毒 血清型分类
Dengue virus serotype classification from complete genomes using a Transformer with chunk-based sequence modeling and explainability analysis
Authors: Francesca Galeone, Nicola Altini, Mariapia Toscanelli, Davide Cacchiarelli, Anna De Filippis, Massimiliano Galdiero, Antonio Brunetti, Gian Maria Zaccaria, Vitoantonio Bevilacqua
Journal: Frontiers in Genetics | Canonical publication date: 2026-09-09 | DOI: 10.3389/fgene.2026.1910877
A 高优先级学术文献 · 研究基因组分析确定了野生埃及伊蚊登革热 媒介 蚊子 宿主 摄食行为的候选超基因架构
Genomic analysis identifies candidate supergene architecture for host-feeding behavior in wild Aedes aegypti dengue vector mosquitoes
Authors: Devojit Kumar Sarma, Sudeesh Warkare, Sweta Mishra, Deepanker Das, Lokendra Rathod, Manoj Kumawat, Siddharth Singh Tomar, Samradhi Singh, Manoj Kumar, Rajnarayan R. Tiwari
Journal: International Journal of Intelligent Engineering and Systems | Canonical publication date: 2026-09-30 | DOI: 10.22266/ijies2026.0930.35
A 高优先级学术文献 · 研究通过基于情感的网络分析、空间映射和时间动态检查印度尼西亚 Twitter 上与登革热相关的信息传播
Examining Dengue-related Information Diffusion on Indonesian Twitter Through Sentiment-based Network Analysis, Spatial Mapping, and Temporal Dynamics
Authors: Ribka Devina Margaretha, Wiwik Anggraeni
Journal: mBio | Canonical publication date: 2026-09-09 | DOI: 10.1128/mbio.01553-26
A 高优先级学术文献 · 研究登革病毒串联xrRNA之间的结构桥促进外切核酸酶抗性的协调
A structural bridge between dengue virus tandem xrRNAs facilitates coordination of exonuclease resistance
Authors: Elizabeth Spear, Zoe O'Donoghue, Steve L. Bonilla, Kevin P. Larsen, Madeline E. Sherlock, Jeffrey S. Kieft
Journal: Journal of Hazardous Materials Advances | Canonical publication date: 2026-09-05 | DOI: 10.1016/j.hazadv.2026.101554
A 高优先级学术文献 · 研究通过脱落动力学和 RNA 稳定性分析优化废水中的 监测:对预警系统的影响
Optimizing dengue virus surveillance in wastewater through shedding dynamics and RNA stability analysis: Implications for early warning systems
Authors: Wenhui Liu, Wenzhe Su, Chanjuan Qu, Haoran Chen, Linan Wu, Yingjun Zhang, Minghao Li, Ling Yuanli, Qinglian Liu, Huiwen Wu
Journal: Surgical Neurology International | Canonical publication date: 2026-09-04 | DOI: 10.25259/sni_731_2026
A 高优先级学术文献 · 综述登革热后的暴发性急性播散性脑脊髓炎的去骨瓣减压术:病例报告及文献综述
Decompressive hemicraniectomy for fulminant acute disseminated encephalomyelitis following dengue fever: Case report and literature review
Authors: José Luis Quelho Filho, Paulo Eduardo Albuquerque Zito Raffa, Henrique Francisco Santana, Ayanne Alves de Oliveira, Gabriel Nunes Melo Assunção, Leonardo Vieira Nunes, Leonardo Peixoto Garcia, Lucas Crociati Meguins
Journal: Viruses | Canonical publication date: 2026-09-09 | DOI: 10.3390/v18090995
A 高优先级学术文献 · 综述利用环保纳米技术靶向登革热病毒蛋白:抗病毒药物 研究的一条有希望的道路
Targeting Dengue Viral Proteins with Eco-Friendly Nanotechnology: A Promising Path for Antiviral Research
Authors: D Madan Kumar, R. Raj Bharath, P. Venkataraman, Kumar Sivasubramanian, Leelavathi Prakasam
Journal: International Journal of Statistics in Medical Research | Canonical publication date: 2026-09-08 | DOI: 10.6000/1929-6029.2026.15.34
A 高优先级学术文献 · 研究预测东部苏丹2023年登革热临床严重程度:使用常规数据对统计模型和机器学习模型的比较分析
Predicting Dengue Clinical Severity in Eastern Sudan's 2023 Outbreak: A Comparative Analysis of Statistical and Machine Learning Models Using Routine Surveillance Data
Authors: Fathelrhman EL Guma, Elkhatim Abuelysar, EihabAbdelhai Osman, Bashir ElnourElbashir Mukhtar, Mumdouh M.M. Hassan, Alshaikh A. Shokeralla
Journal: Frontiers in Epidemiology | Canonical publication date: 2026-09-08 | DOI: 10.3389/fepid.2026.1906738
A 高优先级学术文献 · 研究厄瓜多尔2011–2024年登革热住院率海拔上升与局部热异常:一项全国生态学研究
Local thermal anomalies and the altitudinal rise of dengue hospitalisation rates in Ecuador, 2011–2024: a national ecological study
Authors: Jaime Angamarca-Iguago, Jaen Cagua-Ordoñez, Juan Marcos Parise-Vasco, Daniel Simancas-Racines
Journal: Microorganisms | Canonical publication date: 2026-09-07 | DOI: 10.3390/microorganisms14091969
A 高优先级学术文献 · 研究新生儿登革热感染在流行地区可能模拟晚发性新生儿脓毒症:一个病例报告系列及一个关于抗菌药物管理的诊断框架提案
Neonatal Dengue Infection Mimicking Late-Onset Neonatal Sepsis in Endemic Regions: A Case Report Series and a Proposed Diagnostic Framework for Antimicrobial Stewardship
Authors: Andrés Felipe Arias, Camilo Acosta-Parada, Yaimy Valencia, Maria Paula Guerrero, Catalina Jaramillo, Andrés Arias-Sanchez
Journal: International Journal of Intelligent Engineering and Systems | Canonical publication date: 2026-09-30 | DOI: 10.22266/ijies2026.0930.34
A 高优先级学术文献 · 研究基于自适应门控融合的多模态框架,用于识别 YouTube 上登革出血热信息传播的影响者
An Adaptive Gated Fusion-based Multimodal Framework for Influential Actor Identification in Dengue Haemorrhagic Fever Information Dissemination on YouTube
Authors: Ayu Eka Lestari, Wiwik Anggraeni
Journal: Comparative biochemistry and physiology. Toxicology & pharmacology : CBP | Canonical publication date: 2026-09-08 | DOI: 10.1016/j.cbpc.2026.110690
A 高优先级学术文献 · 研究环境BPA暴露促进黄病毒复制并延长蚊虫寿命。
Environmental BPA exposure promotes flavivirus replication and extends mosquito lifespan.
Authors: Ying Zeng, Fan Yang, Tong Li, Yalan Huang, Tengyingzi Liu, Xiaolu Shi, Xiaoping Xiao
Journal: The Journal of international medical research | Canonical publication date: 2026-09-08 | DOI: 10.1177/03000605261481613
A 高优先级学术文献 · 综述越南住院儿童登革热伴警告征象的临床和流行病学特征:一项横断面研究。
Clinical and epidemiological characteristics of dengue with warning signs among hospitalized children in Vietnam: A cross-sectional study.
Authors: Yen Nguyen Thi Ngoc, Phong Nguyen Doan, Trung Nguyen Quang, Lien Tran Thi, Linh Dang Viet, Nhung Pham Thi, Linh Dang Phuong, Chuc Dang Van
Journal: Abdimas Polsaka | Canonical publication date: 2026-09-04 | DOI: 10.35816/abdimaspolsaka.v5i2.480
A 高优先级学术文献 · 研究基于社区的健康教育改善登革出血热预防知识:来自印度尼西亚一项干预前后的证据
Community-based health education improves knowledge of dengue hemorrhagic fever prevention: evidence from a pre–post intervention in indonesia
Authors: Netty Budi Lestari, Yuli Peristiowati, Suriani Bahrun, Dian Meiliani Yulis
Journal: Scientific Reports | Canonical publication date: 2026-09-05 | DOI: 10.1038/s41598-026-70387-8
A 高优先级学术文献 · 研究利用空间自相关和环境不一致分析探讨也门选定省份登革热攻击率的环境驱动因素和时空异质性
Environmental drivers and spatiotemporal heterogeneity of dengue attack rates across selected Yemeni governorates using spatial autocorrelation and environmental discordance analysis
Authors: Ibrahim Ahmed Ahmed Alhothily, Agus Naba, Magdah Abdulwali Mohammed Al-Shaibah, Nazri Che Dom
Journal: Borneo Nursing Journal (BNJ) | Canonical publication date: 2026-09-07 | DOI: 10.61878/bnj.v8i2b.1422
A 高优先级学术文献 · 研究登革热患者血小板计数和血红蛋白浓度检查结果分析:Ngaglik 1卫生中心案例
Gambaran Hasil Pemeriksaan Jumlah Trombosit dan Hematokrit Pada Pasien Dengue Di Puskesmas Ngaglik 1
Authors: Sefi Fadila, Rosmita Anggraeni, Tri Dyah Astuti
Journal: DOENÇAS INFECTOCONTAGIOSAS PARASITÁRIAS NEGLIGENCIADAS NO BRASIL: IMPACTO SOCIAL E PROSPECÇÕES CONTEMPORÂNEAS | Canonical publication date: 2026-09-07 | DOI: 10.58871/220568.c08
A 高优先级学术文献 · 研究登革热(DENV)
DENGUE (DENV)
Authors: Ana Madalena dos Santos Silva Brito, Josenildo Freitas Nunes Júnior, Taline de Vasconcelos Carvalho, Jorge Guilherme Ricardo Cardoso, Gustavo Henrique da Silva, Alexandre Muller Zigmundo da Silva Leite, Elayne Rayane Diniz Melo, Risonildo Pereira Cordeiro
Journal: Journal of Chemical Information and Modeling | Canonical publication date: 2026-09-04 | DOI: 10.1021/acs.jcim.6c01334
A 高优先级学术文献 · 研究pH和温度对登革病毒包膜二聚体的协同效应:来自微秒分子动力学模拟的见解
Synergistic Effects of pH and Temperature on Dengue Virus Envelope Dimers: Insights from Microsecond Molecular Dynamics Simulations
Authors: Georcki Ropón‐Palacios, Luís Gustavo Fávaro Crespi, Ingrid Bernardes Santana Martins, Walter Rocchia, Alexandre S. de Araujo, Georcki Ropón-Palacios
Journal: Tropical Medicine and Infectious Disease | Canonical publication date: 2026-09-09 | DOI: 10.3390/tropicalmed11090253
A 高优先级学术文献 · 研究德里城市低收入群体中登革热和寨卡病毒的血清流行率:一项横断面和嵌套纵向研究
Dengue and Chikungunya Seroprevalence in an Urban Low-Income Cohort in Delhi: A Cross-Sectional and Nested Longitudinal Study
Authors: Nandini Sharma, Saurav Basu, Shivani Rao, Mrunali Zode, Himanshu Bachawandia, Meenakshi Bakshi, Mongjam Meghachandra Singh
Journal: Bangladesh Journal of Infectious Diseases | Canonical publication date: 2026-09-08 | DOI: 10.3329/bjid.v13i1.92741
A 高优先级学术文献 · 研究孟加拉国库尔纳市三级医院中登革热患者血小板指标按血小板计数分层分析
Platelet Indices in Dengue Patients Stratified by Platelet Count in a Tertiary Care Hospital of Khulna City of Bangladesh
Authors: Tasnim Rahman, Abdullah Al Faroque, Mohammad Monzurul Alam Bhuiyan, Toufiq Ahmed, Shaikh Badiuzzaman, Mahmuda Jahan, Suraiya Yasmin
Journal: ChemRxiv | Canonical publication date: 2026-09-04 | DOI: 10.26434/chemrxiv.15008305/v1
A 高优先级学术文献 · 研究计算屏蔽登革病毒前融合结构的渗透性环状微型肽构象候选物
Computational shielding of dengue viral prefusion with permeable cyclic-minipeptides
Authors: Julio Coll
Journal: Asian Journal of Research in Infectious Diseases | Canonical publication date: 2026-09-05 | DOI: 10.9734/ajrid/2026/v17i10579
A 高优先级学术文献 · 研究基于外周血单核细胞转录组的登革热相关共病及关键调控基因的计算识别
Computational Identification of Dengue-Associated Comorbidities and Key Regulatory Genes from Peripheral Blood Mononuclear Cell Transcriptomes
Authors: Adrita Alam, Rupa Dey, Chaity Paul, Muezz Uddin, A. F. M. Mahbubur Rahman, Sanjoy Kumar Chakravarty, Somlal Das, Md. Humayun Kabir
Journal: Journal of Biomedical Advancement Scientific Research | Canonical publication date: 2026-09-05 | DOI: 10.63721/26jbasr0159
A 高优先级学术文献 · 研究菲律宾黎刹公立医院的登革热患者和医疗保健专业人员的经验
Experiences of Dengue Patients and Healthcare Professionals in Public Hospitals of Rizal, Philippines
Authors: Emmanuelle Reigne B. Tica
Journal: DELOS Desarrollo Local Sostenible | Canonical publication date: 2026-09-04 | DOI: 10.55905/rdelosv19.n84-089
A 高优先级学术文献 · 研究巴西登革热流行病学、这种被忽视的热带疾病的总体特征以及疫苗接种作为预防手段
Epidemiologia da dengue no Brasil, características gerais dessa doença tropical negligenciada e a vacinação como forma de prevenção
Authors: Milena Bitencourt Santos, Maria Luiza de Oliveira Nogueira, Érika Maria Henriques Monteiro, Thiago César Nascimento, Igor Rosa Meurer
Journal: Unknown Journal | Canonical publication date: 2026-09-07 | DOI: 10.20944/preprints202609.0499.v1
B 常规重要学术文献 · 研究巴西全国城市登革热预测中共享学习的运用:历史、气候与模型权衡的证据
Shared Learning for Nationwide Municipal Dengue Incidence Forecasting in Brazil: Evidence on History, Climate, and Model Trade-Offs
Authors: Rhibull Tang
Journal: IVY ENBER SCIENTIFIC JOURNAL | Canonical publication date: 2026-11-02 | DOI: 10.57108/iesj.2026.6-1.1
B 常规重要学术文献 · 研究登革热流行病学和社会人口学视角:米纳斯吉拉斯州的现状分析
A dengue sob uma perspectiva epidemiológica e sociodemográfica: uma análise sobre o estado de Minas Gerais
Authors: Maria Cristina Vasconcelos Teixeira
Journal: Probiotics and antimicrobial proteins | Canonical publication date: 2026-09-05 | DOI: 10.1007/s12602-026-11199-0
C 补充信息学术文献 · 综述抗病毒药物药物研发中的蝎子肽:深入综述。
Scorpion Peptides in Antiviral Drug Discovery: An In-depth Review.
Authors: Mojtaba Memariani, Hamed Memariani
Journal: Molecular biology reports | Canonical publication date: 2026-09-04 | DOI: 10.1007/s11033-026-12713-x
C 补充信息学术文献 · 综述PTBP1在宿主病毒界面的作用:病毒RNA翻译、复制和免疫调节的机制角色
PTBP1 at the host-virus interface: mechanistic roles in viral RNA translation, replication, and immune modulation.
Authors: Kajal, Achyut Pandey, Rajesh Yadav, Rishikesh Shukla, Shruti Mishra
Journal: ChemMedChem | Canonical publication date: 2026-09-14 | DOI: 10.1002/cmdc.70435
C 补充信息学术文献 · 研究发现具有广谱 抗病毒药物 活性的 4'-叠氮基 Fleximer 核苷类似物,可对抗 DENV、EBOV 和其他 RNA 病毒。
Discovery of a 4'-Azido Fleximer Nucleoside Analog With Broad-Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses.
Authors: Kyle A Davis, Ryan L Slack, Thomas R Foulkes, Tereza Frčková, Lenka Tomková, Jessica L Smith, Meareg Amare, Grayson D Pipher, Peter Halfmann, Alec J Hirsch🚨 突发动态与新闻
Published: 2026-09-06 | Publisher: World Health Organization (WHO)
A 高优先级公共卫生新闻世界卫生组织(WHO)"Shastho Chorcha"对话将政府与社会整体行动置于登革热应对的核心 - 世界卫生组织(WHO)
WHO “Shastho Chorcha” dialogue puts whole-of-government, whole-of-society action at the centre of dengue response - World Health Organization (WHO)
新闻五要素时间该事件于2026年9月9日被报道,相关活动于2026年9月16日举行。地点与对象该事件与全球卫生倡议相关,特别提到了不丹和东帝汶作为参与卫生相关验证的国家。事件世卫组织举办名为"Shastho Chorcha"的对话,以强调在登革热应对中采取政府与社会整体行动。这是世界卫生组织的官方声明。规模、影响与风险此次对话聚焦于提升全球登革热应对策略,但证据中未报告具体病例数、死亡数或暴露人数。应对、状态与不确定性此次对话是世卫组织的官方举措,表明其持续努力应对登革热。未提供具体调查或检测细节。
Published: 2026-09-04 | Publisher: Bioengineer.org
B 常规重要公共卫生新闻TAK-003登革热疫苗在巴西圣保罗州2024–2025暴发期间保护青少年 - Bioengineer.org
TAK-003 dengue vaccine protects adolescents during São Paulo’s 2024–2025 outbreak - Bioengineer.org
新闻五要素时间该研究是在2024–2025年登革热暴发期间在圣保罗进行的,研究结果的发表日期为2026-09-04。分析涵盖了为期一年的青少年数据。地点与对象该研究在巴西圣保罗州进行,重点关注10至15岁的青少年群体。研究人群包括384,546人,其中166,390人参与了分析。事件一项真实世界评估在TAK-003登革热疫苗上进行,结果显示单剂量仍可预防约60%的有症状登革热病例和75%的住院情况,接种后一年。该研究由巴西马托格罗索州联邦大学、美国佛罗里达大学和耶鲁公共卫生学院...规模、影响与风险研究发现,疫苗对有症状登革热的有效性为单剂量59.2%、双剂量73.1%。对住院的有效性为单剂量74.6%、双剂量87.9%。研究还指出,在暴发期间,主导的病毒血清型发生了变化,DENV-3重新出现...应对、状态与不确定性该研究使用了巴西强制登革热监测系统(SINAN-Dengue)和圣保罗州的疫苗接种登记数据。研究结果发表在eClinicalMedicine上,研究人员承认存在局限性,包括缺乏基线血清状态和轻度感染...
Published: 2026-09-04 | Publisher: Sarasota Herald-Tribune
B 常规重要公共卫生新闻佛罗里达登革热病例激增。劳动节周末如何保护自己 - 萨拉索塔先驱报
Florida dengue cases spike. How to protect yourself on Labor Day weekend - Sarasota Herald-Tribune
新闻五要素时间Published on 2026-09-04. The surge in dengue cases was reported as of late August and Aug. 29, with...地点与对象佛罗里达州,特别是希尔斯伯勒县,占报告的73例中的59例。其他受影响的县包括迈阿密-戴德县、棕榈滩县、帕斯科县和皮尼拉斯县。面临风险的人群包括数百万计划在劳动节周末进行户外活动的佛罗里达居民。事件佛罗里达州登革热病例激增,截至8月底已报告73例本地感染病例。佛罗里达州卫生部确认希尔斯伯勒县有14个蚊虫池检测出DENV-2病毒,且病例激增正值人们准备迎接劳动节周末之际。规模、影响与风险截至8月底,佛罗里达州报告了73例登革热病例,其中59例来自希尔斯伯勒县。卫生部门还指出,有136例病例来自曾前往登革热流行国家的旅行者。登革热可能导致严重并发症,如登革热出血,若不及时治疗可能致命...应对、状态与不确定性佛罗里达州卫生部已对多个县发布蚊媒疾病警示,包括希尔斯伯勒县、迈阿密-戴德县和皮尼拉斯县。他们建议使用EPA注册的驱蚊剂,并采取措施防止蚊虫繁殖。目前情况正在积极监测中,卫生部门正敦促公众采取预防措...
Published: 2026-09-08 | Publisher: ThePrint
B 常规重要公共卫生新闻WHO has zeroed in on 6 candidates for a dengue drug, but only 1 in late-stage trials - ThePrint
WHO has zeroed in on 6 candidates for a dengue drug, but only 1 in late-stage trials - ThePrint
新闻五要素时间The report was published on September 8, 2026. The WHO analysis was published this month, and the P...地点与对象The WHO analysis is global, but the Phase 3 trial for VIS513 is specifically mentioned to be enroll...事件The World Health Organization (WHO) has identified six dengue drug candidates with evidence warrant...规模、影响与风险The WHO reported over 5 million cases and more than 5,000 deaths in 2023 across 80+ countries. Abou...应对、状态与不确定性The WHO analysis is ongoing, with researchers reviewing 21 trial records. The Phase 3 trial for VIS...
Published: 2026-09-07 | Publisher: GMA Network
B 常规重要公共卫生新闻菲律宾卫生部8月2日至15日记录超过15000例登革热病例,高于前一时期 - GMA Network
DOH logs over 15k dengue cases from Aug 2 to 15, higher than previous period - GMA Network
新闻五要素时间菲律宾卫生部于2026年8月29日报告了这些数据。所涵盖的时间段为2026年8月2日至15日。地点与对象该报告涉及菲律宾全国范围内的登革热病例。受影响的人群包括在指定时间段内感染登革热的个体。事件菲律宾卫生部记录了2026年8月2日至15日的15,763例登革热病例,比前一个两周时期(2026年7月19日至8月1日)增加了9%。规模、影响与风险截至2026年,菲律宾卫生部已记录128,634例登革热病例,当前数量比2025年同期的209,631例下降了39%。登革热是一种由蚊子传播的病毒感染,感染第二种血清型的人群风险更高。应对、状态与不确定性菲律宾卫生部已准备好应对登革热病例的潜在激增,为血库和实验室检测储备了物资。他们还呼吁公众避免涉水、保持卫生并清除蚊子繁殖地。
Published: 2026-09-08 | Publisher: Bing News RSS
B 常规重要公共卫生新闻佛罗里达州正面临又一波病毒威胁激增:登革热
Florida Is Confronting Yet Another Surging Viral Threat: Dengue Fever
新闻五要素时间2026-09-08,事件日期为文章发布当日(2026-09-08),截至当年第三个月的第三天(2026-09-08)仍持续。地点与对象佛罗里达州,特别是坦帕地区,重点关注居民和当地的蚊子种群。事件佛罗里达州正经历登革热病例激增,佛罗里达州卫生部尚未确认诊断及死亡病例,但这种情况似乎预示着该州可能面临严峻的公共卫生挑战。该事件由坦帕湾时报和Jezebel报道,盖伊·斯莫尔这位80岁女性的死亡被...规模、影响与风险据CDC报告,佛罗里达州在2026年已有超过200例登革热病例,其中至少60例被认为涉及本地传播。由于气候变化和全球病例增加,佛罗里达州卫生部正在采取措施中断蚊子生命周期,本地传播的风险正在上升。应对、状态与不确定性佛罗里达州卫生部正在进行调查并实施蚊虫控制措施,包括使用直升机喷洒杀虫剂。居民被建议在喷洒期间留在室内并清除积水。由于提及了政治和社会背景,来源评估尚不明确,且由于诊断及死亡病例尚未确认,信心程度中...
Published: 2026-09-08 | Publisher: daily-sun.com
B 常规重要公共卫生新闻登革热需要疫苗行动 - daily-sun.com
Dengue demands vaccine action - daily-sun.com
新闻五要素时间The dengue outbreak in Bangladesh has been escalating since June, with the highest single-day figur...地点与对象孟加拉国,重点关注全国层面,由卫生服务总监部(DGHS)追踪该国登革热的传播情况。面临风险的人群包括所有个体,尤其是生活在埃及伊蚊繁殖地的地区居民。事件A dengue outbreak is ongoing in Bangladesh, with 1,571 new cases and nine deaths reported in the 24...规模、影响与风险As of 08 September 2026, Bangladesh has recorded 45,475 dengue cases and 130 deaths. The outbreak i...应对、状态与不确定性政府已启动一项从2026年9月10日开始的为期三个月的特别清洁和公众意识宣传活动。外科医生被指示加强医院准备,优先处理登革热患者,并提供免费登革热检测。然而,目前孟加拉国尚未确认使用任何登革热疫苗,...🗂️ 补充新闻
Experimental Dengue Antibody Cleared Fever and Virus Within a Single Day at All Four Doses Tested - Medical Daily
Experimental Dengue Antibody Cleared Fever and Virus Within a Single Day at All Four Doses Tested - Medical Daily
2026-09-04 · Medical Daily
Florida Logged 32 Local Dengue Cases in One Week, and Tampa Bay Now Holds 65 of 73 - Medical Daily
Florida Logged 32 Local Dengue Cases in One Week, and Tampa Bay Now Holds 65 of 73 - Medical Daily
2026-09-09 · Medical Daily
Anna Paulina Luna Warns of Rise In Dengue Fever Cases - floridianpress.com
Anna Paulina Luna Warns of Rise In Dengue Fever Cases - floridianpress.com
2026-09-08 · floridianpress.com
Dengue fever is spreading. Here are 5 tips to help avoid it.
Dengue fever is spreading. Here are 5 tips to help avoid it.
2026-09-09 · Bing News RSS
Florida dengue cases climb fast, symptoms you should not ignore - latination.com
Florida dengue cases climb fast, symptoms you should not ignore - latination.com
2026-09-07 · latination.com
Tampa Bay Battles Worst Dengue Fever Outbreak In Nearly A Century As Cases Double In A Week Officials Say
Tampa Bay Battles Worst Dengue Fever Outbreak In Nearly A Century As Cases Double In A Week Officials Say
2026-09-06 · Bing News RSS
Dengue virus detected in wastewater sample from Hawaiʻi Island - Maui Now
Dengue virus detected in wastewater sample from Hawaiʻi Island - Maui Now
2026-09-04 · Maui Now
Florida Is Confronting Yet Another Surging Viral Threat: Dengue Fever - Yahoo
Florida Is Confronting Yet Another Surging Viral Threat: Dengue Fever - Yahoo
2026-09-08 · Yahoo
EsSalud Reinforces Dengue Surveillance as El Niño Threatens Peru - streamlinefeed.co.ke
EsSalud Reinforces Dengue Surveillance as El Niño Threatens Peru - streamlinefeed.co.ke
2026-09-04 · streamlinefeed.co.ke
Florida Mosquito Control Ramps Up Effort as Dengue Cases Surge - SuaraGarut.ID
Florida Mosquito Control Ramps Up Effort as Dengue Cases Surge - SuaraGarut.ID
2026-09-07 · SuaraGarut.ID
Experimental Monoclonal Antibody Shows Therapeutic Promise Against Dengue: JAMA - Medical Dialogues
Experimental Monoclonal Antibody Shows Therapeutic Promise Against Dengue: JAMA - Medical Dialogues
2026-09-07 · Medical Dialogues
Dengue Outbreak Escalates: Bangladesh Hospitals Strained as Cases Surge - Devdiscourse
Dengue Outbreak Escalates: Bangladesh Hospitals Strained as Cases Surge - Devdiscourse
2026-09-07 · Devdiscourse
Dengue cases in Pakistan rose by over 3,000pc in 11 years: study - dawn.com
Dengue cases in Pakistan rose by over 3,000pc in 11 years: study - dawn.com
2026-09-09 · dawn.com
Quick takes: Dengue rise in Florida, South Dakota anthrax detection, drop in foreign food inspections - cidrap.umn.edu
Quick takes: Dengue rise in Florida, South Dakota anthrax detection, drop in foreign food inspections - cidrap.umn.edu
2026-09-08 · cidrap.umn.edu
Dengue fever is spreading. Here are 5 tips to help avoid it. - Yahoo
Dengue fever is spreading. Here are 5 tips to help avoid it. - Yahoo
2026-09-09 · Yahoo
Mathematical Modelling of the Impact of Misdiagnosis on Dengue-Malaria Co-Infection Dynamics ()
Mathematical Modelling of the Impact of Misdiagnosis on Dengue-Malaria Co-Infection Dynamics ()
2026-09-08 · Bing News RSS
Florida Dengue Cases Rise: Why Local Infections Are Increasing - Health and Me
Florida Dengue Cases Rise: Why Local Infections Are Increasing - Health and Me
2026-09-08 · Health and Me
Dengue cases soar 66pc, deaths hit 62 in Malaysia, almost double 2025 toll - malaysia.news.yahoo.com
Dengue cases soar 66pc, deaths hit 62 in Malaysia, almost double 2025 toll - malaysia.news.yahoo.com
2026-09-09 · malaysia.news.yahoo.com
Florida reports spike in dengue fever cases, health alerts issued
Florida reports spike in dengue fever cases, health alerts issued
2026-09-08 · Bing News RSS
Florida Battles Rising Dengue Cases as Mosquito Threat Grows - Tori News
Florida Battles Rising Dengue Cases as Mosquito Threat Grows - Tori News
2026-09-08 · Tori News
Florida dengue cases spike. How to protect yourself on Labor Day weekend
Florida dengue cases spike. How to protect yourself on Labor Day weekend
2026-09-04 · Bing News RSS
Health dept intensifies dengue surveillance - timesofindia.indiatimes.com
Health dept intensifies dengue surveillance - timesofindia.indiatimes.com
2026-09-07 · timesofindia.indiatimes.com
Orange County increases mosquito control efforts in Pine Hills after dengue case - Spectrum News 13
Orange County increases mosquito control efforts in Pine Hills after dengue case - Spectrum News 13
2026-09-06 · Spectrum News 13
Dengue Fever Cases Rise 66 Per Cent - Fahmi - Bernama
Dengue Fever Cases Rise 66 Per Cent - Fahmi - Bernama
2026-09-09 · Bernama
Dengue Fever Cases Rise 66 Per Cent - Fahmi
Dengue Fever Cases Rise 66 Per Cent - Fahmi
2026-09-09 · Bing News RSS
Equip yourself with a 'double shield' to proactively respond to the peak season of dengue fever. - Vietnam.vn
Equip yourself with a 'double shield' to proactively respond to the peak season of dengue fever. - Vietnam.vn
2026-09-07 · Vietnam.vn
Hillsborough Leads Florida as Dengue Cases Double - NewsRadio WFLA
Hillsborough Leads Florida as Dengue Cases Double - NewsRadio WFLA
2026-09-04 · NewsRadio WFLA
Hillsborough County is Florida’s dengue epicenter as locally acquired cases rise - Yahoo
Hillsborough County is Florida’s dengue epicenter as locally acquired cases rise - Yahoo
2026-09-04 · Yahoo
Indonesia Develops mRNA-Based Dengue Vaccine to Fight Four Virus Serotypes - VOI.ID
Indonesia Develops mRNA-Based Dengue Vaccine to Fight Four Virus Serotypes - VOI.ID
2026-09-07 · VOI.ID
Delhi government holds workshop for MLAs and councillors on H1N1 and dengue prevention - The News Mill
Delhi government holds workshop for MLAs and councillors on H1N1 and dengue prevention - The News Mill
2026-09-07 · The News Mill
Surgeon general urges precautions against dengue - FOX 13 Tampa Bay
Surgeon general urges precautions against dengue - FOX 13 Tampa Bay
2026-09-04 · FOX 13 Tampa Bay
Family Says Tampa Woman Died From Dengue Fever On 80th Birthday: Reports - Patch
Family Says Tampa Woman Died From Dengue Fever On 80th Birthday: Reports - Patch
2026-09-09 · Patch
A Tampa woman was diagnosed with dengue fever. Within a week, she was dead. - Yahoo
A Tampa woman was diagnosed with dengue fever. Within a week, she was dead. - Yahoo
2026-09-08 · Yahoo
Inside the fight against mosquitoes spreading dengue fever in Florida - Tampa Bay Times
Inside the fight against mosquitoes spreading dengue fever in Florida - Tampa Bay Times
2026-09-04 · Tampa Bay Times
Dengue Fever Surge in Tampa Bay: Helicopter Spraying Underway in Hillsborough and Pasco Counties
Dengue Fever Surge in Tampa Bay: Helicopter Spraying Underway in Hillsborough and Pasco Counties
2026-09-07 · Bing News RSS
Hillsborough County is Florida’s dengue epicenter as locally acquired cases rise - wtsp.com
Hillsborough County is Florida’s dengue epicenter as locally acquired cases rise - wtsp.com
2026-09-04 · wtsp.com
Chattogram doctors warn of dengue 'critical phase' as cases rise
Chattogram doctors warn of dengue 'critical phase' as cases rise
2026-09-04 · Bing News RSS
Dengue may take severe turn in October, warns State Minister - Views Bangladesh
Dengue may take severe turn in October, warns State Minister - Views Bangladesh
2026-09-06 · Views Bangladesh
Twelve people have died of dengue in Iloilo province from Jan. 4 to Aug. 29, even as total cases fell 39% from the same period last year, the Iloilo Provincial Health Office reported. Link to the full story in comment section. - facebook.com
Twelve people have died of dengue in Iloilo province from Jan. 4 to Aug. 29, even as total cases fell 39% from the same period last year, the Iloilo Provincial Health Office reported. Link to the full story in comment section. - facebook.com
2026-09-05 · facebook.com
Dengue cases rise in Florida, CDC data show - mysuncoast.com
Dengue cases rise in Florida, CDC data show - mysuncoast.com
2026-09-04 · mysuncoast.com
Bacolod logs 3 fatalities, 40% drop in dengue cases - mb.com.ph
Bacolod logs 3 fatalities, 40% drop in dengue cases - mb.com.ph
2026-09-04 · mb.com.ph
BACOLOD: Bacolod logs three dengue deaths amid 448 cases - rpnradio.com
BACOLOD: Bacolod logs three dengue deaths amid 448 cases - rpnradio.com
2026-09-04 · rpnradio.com
Dengue fever in Kenya: cases are on the rise, but there's no cause for concern for travellers - MalindiKenya.net
Dengue fever in Kenya: cases are on the rise, but there's no cause for concern for travellers - MalindiKenya.net
2026-09-06 · MalindiKenya.net
Dengue is a daytime threat: Why travellers to hotspots areas need to rethink mosquito protection - The Eastleigh Voice
Dengue is a daytime threat: Why travellers to hotspots areas need to rethink mosquito protection - The Eastleigh Voice
2026-09-07 · The Eastleigh Voice
A Tampa woman was diagnosed with dengue fever. Within a week, she was dead. - Tampa Bay Times
A Tampa woman was diagnosed with dengue fever. Within a week, she was dead. - Tampa Bay Times
2026-09-09 · Tampa Bay Times
‘She met the wrong mosquito’: Family says 80-year-old Tampa woman died from dengue fever
‘She met the wrong mosquito’: Family says 80-year-old Tampa woman died from dengue fever
2026-09-08 · Bing News RSS
Dengue arrives locally as mosquitoes draw attention - chronicleonline.com
Dengue arrives locally as mosquitoes draw attention - chronicleonline.com
2026-09-08 · chronicleonline.com
Dengue Fever Surge in Tampa Bay: Helicopter Spraying Underway in Hillsborough and Pasco Counties - News Talk Florida
Dengue Fever Surge in Tampa Bay: Helicopter Spraying Underway in Hillsborough and Pasco Counties - News Talk Florida
2026-09-07 · News Talk Florida
Dengue fever is spreading. Here are 5 tips to help avoid it. - Tampa Bay Times
Dengue fever is spreading. Here are 5 tips to help avoid it. - Tampa Bay Times
2026-09-09 · Tampa Bay Times
Florida dengue cases rise: Why local infections are increasing in US
Florida dengue cases rise: Why local infections are increasing in US
2026-09-08 · Bing News RSS
Dengue cases nearly double in one week. Here's where
Dengue cases nearly double in one week. Here's where
2026-09-08 · Bing News RSS
Bangladesh dengue outbreak accelerates as hospitals come under strain
Bangladesh dengue outbreak accelerates as hospitals come under strain
2026-09-06 · Bing News RSS
DENV-3 dominance raises alarm
DENV-3 dominance raises alarm
2026-09-09 · Bing News RSS
X user shares long recovery journey after getting dengue thrice in 18 months: ‘Mosquitoes have a type’ - The Indian Express
X user shares long recovery journey after getting dengue thrice in 18 months: ‘Mosquitoes have a type’ - The Indian Express
2026-09-08 · The Indian Express
Helicopters set to spray Tampa overnight after dengue virus detected in mosquitoes
Helicopters set to spray Tampa overnight after dengue virus detected in mosquitoes
2026-09-08 · Bing News RSS
‘She met the wrong mosquito’: Family says 80-year-old Tampa woman died from dengue fever - WFLA
‘She met the wrong mosquito’: Family says 80-year-old Tampa woman died from dengue fever - WFLA
2026-09-09 · WFLA
Three die, 1,463 hospitalised with dengue fever in a day
Three die, 1,463 hospitalised with dengue fever in a day
2026-09-09 · Bing News RSS
Dengue fever: Locally acquired cases surge to 65 across Bay Area
Dengue fever: Locally acquired cases surge to 65 across Bay Area
2026-09-04 · Bing News RSS
Serum Institute-Led Monoclonal Antibody Clears Dengue Viremia, Fever Within A Day In Phase 2 Trial - Health and Me
Serum Institute-Led Monoclonal Antibody Clears Dengue Viremia, Fever Within A Day In Phase 2 Trial - Health and Me
2026-09-04 · Health and Me
They urge people not to let their guard down despite the decrease in dengue cases - Universidad de Guadalajara
They urge people not to let their guard down despite the decrease in dengue cases - Universidad de Guadalajara
2026-09-09 · Universidad de Guadalajara
Fever Dropped But Still Weak? Why Days 4 To 6 Of Dengue Are The Most Dangerous - NDTV
Fever Dropped But Still Weak? Why Days 4 To 6 Of Dengue Are The Most Dangerous - NDTV
2026-09-08 · NDTV
Bangladesh dengue outbreak accelerates as hospitals come under strain - The Straits Times
Bangladesh dengue outbreak accelerates as hospitals come under strain - The Straits Times
2026-09-07 · The Straits Times
Bangladesh dengue outbreak accelerates as hospitals come under strain - Reuters
Bangladesh dengue outbreak accelerates as hospitals come under strain - Reuters
2026-09-07 · Reuters
Helicopters spray Tampa neighborhoods as dengue cases climb - Bay News 9
Helicopters spray Tampa neighborhoods as dengue cases climb - Bay News 9
2026-09-06 · Bay News 9
A Tampa woman was diagnosed with dengue fever. Within a week, she was dead.
A Tampa woman was diagnosed with dengue fever. Within a week, she was dead.
2026-09-08 · Bing News RSS
Hillsborough County leads Florida dengue fever cases as total doubles in 1 week - wkrg.com
Hillsborough County leads Florida dengue fever cases as total doubles in 1 week - wkrg.com
2026-09-04 · wkrg.com
Hillsborough County called ‘epicenter’ of locally acquired dengue cases in Florida - WFLA
Hillsborough County called ‘epicenter’ of locally acquired dengue cases in Florida - WFLA
2026-09-04 · WFLA
Florida Department of Health speaks on local cases of dengue fever - Yahoo
Florida Department of Health speaks on local cases of dengue fever - Yahoo
2026-09-04 · Yahoo
Florida Department of Health speaks on local cases of dengue fever - WFLA
Florida Department of Health speaks on local cases of dengue fever - WFLA
2026-09-04 · WFLA
Florida Dengue Fever Cases Reach 73 as Surge Hits Tampa Bay - Readers.id
Florida Dengue Fever Cases Reach 73 as Surge Hits Tampa Bay - Readers.id
2026-09-04 · Readers.id
Dengue fever continues in 2020; the public is warned to take preventative measures. - Universidad de Guadalajara
Dengue fever continues in 2020; the public is warned to take preventative measures. - Universidad de Guadalajara
2026-09-08 · Universidad de Guadalajara
查看完整网页
100 项与 Dengue vaccine tetravalent(Takeda) 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 登革热 | 印尼 | 2022-08-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 30 | 遞鹹鹹製鏇醖醖鹽網鹽(廠鏇鑰艱範繭窪網憲襯) = Vaccine RNAemia and safety findings were consistent with the known TAK-003 safety profile 齋醖衊範蓋鑰蓋艱構願 (遞艱壓襯鑰觸廠蓋遞範 ) 更多 | 积极 | 2026-04-01 | |||
早期临床1期 | 29 | (SC ID) | 構願艱網醖網積衊鹹憲(醖願製簾顧衊鹹鹽廠選) = 廠夢糧衊壓襯齋願艱觸 鹽範鹹觸獵蓋範鹹壓構 (餘築鹽遞壓蓋鏇簾選鬱, 繭顧夢網簾網憲夢鹹鏇 ~ 選廠壓網簾醖鏇糧網蓋) 更多 | - | 2026-01-16 | ||
(SC SC) | 構願艱網醖網積衊鹹憲(醖願製簾顧衊鹹鹽廠選) = 艱鏇製襯製積醖鹽製襯 鹽範鹹觸獵蓋範鹹壓構 (餘築鹽遞壓蓋鏇簾選鬱, 願齋願製餘鹽繭膚醖艱 ~ 鬱選鬱窪願夢醖顧繭繭) 更多 | ||||||
临床2/3期 | 557 | 構構積積鹹鹽廠鏇淵構(衊憲蓋壓網艱醖夢夢鹽) = 網觸鹽壓醖積遞鬱顧夢 窪窪淵衊鏇糧襯築鹹憲 (糧糧糧網餘廠選顧積醖 ) 更多 | 积极 | 2025-12-31 | |||
(Placebo) | 構構積積鹹鹽廠鏇淵構(衊憲蓋壓網艱醖夢夢鹽) = 選糧構鹽衊鏇構積構憲 窪窪淵衊鏇糧襯築鹹憲 (糧糧糧網餘廠選顧積醖 ) 更多 | ||||||
临床3期 | 365 | (Prior to Booster: DEN-304) | 簾廠憲積壓鑰醖遞顧淵(衊窪齋遞範鑰範獵繭積) = 獵觸製蓋鹹鬱淵簾遞壓 淵齋艱夢鹽憲壓繭醖鏇 (製壓選選構窪餘蓋鬱壓, 範觸鏇鑰願觸鏇醖範廠 ~ 願簾衊顧襯願淵願觸憲) 更多 | - | 2025-06-12 | ||
(Prior to Booster: DEN-315) | 簾廠憲積壓鑰醖遞顧淵(衊窪齋遞範鑰範獵繭積) = 蓋淵淵築構醖願鏇鑰築 淵齋艱夢鹽憲壓繭醖鏇 (製壓選選構窪餘蓋鬱壓, 製膚積淵觸築構繭壓蓋 ~ 糧餘蓋範願夢糧築醖衊) 更多 | ||||||
临床3期 | 20,171 | 膚鹽構構糧鬱獵廠壓觸(襯鹽築齋糧鬱衊顧蓋網) = 齋壓齋齋製蓋醖窪鬱築 壓築選糧窪鬱窪顧製淵 (鏇襯窪鬱積淵繭憲夢襯 ) 更多 | 积极 | 2025-05-01 | |||
临床3期 | - | TAK-003 Vaccine | 築積壓網淵夢鑰顧鏇製(鹽繭築觸鬱簾窪鏇衊製) = GMTs remained elevated against all 4 serotypes for ∼4 years postvaccination, with no evident differences across age groups 齋積積範範獵淵鏇願遞 (艱簾壓選遞構襯醖範網 ) | 积极 | 2025-02-05 | ||
临床3期 | 登革热 yellow fever vaccination | - | 夢艱觸憲範鏇選鏇醖鬱(憲齋築衊繭壓膚夢壓鏇) = Within 28 days of any vaccination, the proportions of participants with serious adverse events in the YF/JE prior vaccination population were comparable between the TAK-003 and placebo groups 壓鏇願製顧蓋遞鑰廠範 (遞憲鹽膚襯願鹹齋艱窪 ) | - | 2024-12-16 | ||
临床3期 | 7 | - | 積淵顧築簾憲窪鹹淵鹹(鹹選淵觸鑰觸淵願積顧) = 醖壓構淵蓋範顧獵鏇膚 廠廠遞淵窪膚獵遞繭膚 (廠壓範簾遞夢糧糧構鹽 ) 更多 | 积极 | 2024-08-22 | ||
临床3期 | 614 | 9vHPV Vaccine+Dengue Tetravalent Vaccine (TDV) (9vHPV+TDV) | 鏇窪憲襯壓積齋網壓鹽(糧夢艱鑰窪齋鏇鹽襯憲) = 獵艱廠鑰鏇夢壓鹹鏇選 顧餘夢願艱願顧積醖願 (顧壓鹽醖願築築憲遞簾, 醖鹽淵網顧鬱衊構蓋獵 ~ 積夢製衊製顧鏇網蓋壓) 更多 | - | 2024-02-07 | ||
9vHPV Vaccine (9vHPV) | 鏇窪憲襯壓積齋網壓鹽(糧夢艱鑰窪齋鏇鹽襯憲) = 顧構衊襯衊繭網積遞壓 顧餘夢願艱願顧積醖願 (顧壓鹽醖願築築憲遞簾, 醖鹽鏇膚觸築憲醖鑰窪 ~ 鬱鹽遞鹹憲壓鬱鹹簾製) 更多 | ||||||
临床3期 | 900 | YF-17D+TAK-003 | 醖範憲積鬱鏇願範遞積(獵壓鹹鏇齋範襯艱醖鹹) = 鑰壓鑰襯獵鑰繭齋遞範 遞築壓鬱鏇網夢膚餘鹽 (積觸淵鹽艱蓋構淵壓壓 ) | - | 2023-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用